KR20220163330A - Composition for anti-inflammation comprising extract from Tartary buckwheat - Google Patents
Composition for anti-inflammation comprising extract from Tartary buckwheat Download PDFInfo
- Publication number
- KR20220163330A KR20220163330A KR1020220159678A KR20220159678A KR20220163330A KR 20220163330 A KR20220163330 A KR 20220163330A KR 1020220159678 A KR1020220159678 A KR 1020220159678A KR 20220159678 A KR20220159678 A KR 20220159678A KR 20220163330 A KR20220163330 A KR 20220163330A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- bitter buckwheat
- buckwheat
- low temperature
- hours
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 244000130270 Fagopyrum tataricum Species 0.000 title claims abstract description 16
- 235000014693 Fagopyrum tataricum Nutrition 0.000 title claims description 12
- 206010061218 Inflammation Diseases 0.000 title description 12
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 38
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 38
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 38
- 229960004555 rutoside Drugs 0.000 claims abstract description 38
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 37
- 235000005493 rutin Nutrition 0.000 claims abstract description 37
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 37
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 30
- 230000014509 gene expression Effects 0.000 claims abstract description 28
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 22
- 102000004127 Cytokines Human genes 0.000 claims abstract description 16
- 108090000695 Cytokines Proteins 0.000 claims abstract description 16
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 276
- 238000000605 extraction Methods 0.000 claims description 93
- 239000000843 powder Substances 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 229910001868 water Inorganic materials 0.000 claims description 25
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 21
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 21
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000010025 steaming Methods 0.000 claims description 6
- 230000001747 exhibiting effect Effects 0.000 claims description 2
- 241000219051 Fagopyrum Species 0.000 claims 18
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 42
- 238000004519 manufacturing process Methods 0.000 abstract description 32
- 230000002401 inhibitory effect Effects 0.000 abstract description 21
- 230000003078 antioxidant effect Effects 0.000 abstract description 18
- 229930003935 flavonoid Natural products 0.000 abstract description 16
- 150000002215 flavonoids Chemical class 0.000 abstract description 16
- 235000017173 flavonoids Nutrition 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 5
- 229940080805 fagopyrum esculentum extract Drugs 0.000 abstract 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 259
- 238000012545 processing Methods 0.000 description 171
- 235000013339 cereals Nutrition 0.000 description 56
- 239000000523 sample Substances 0.000 description 33
- 239000008187 granular material Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 21
- 239000000469 ethanolic extract Substances 0.000 description 20
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 19
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 19
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 19
- 235000005875 quercetin Nutrition 0.000 description 19
- 229960001285 quercetin Drugs 0.000 description 19
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 18
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 18
- 239000003963 antioxidant agent Substances 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- 108090001005 Interleukin-6 Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000010421 standard material Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 238000011088 calibration curve Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 239000010903 husk Substances 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- -1 IL-1β Proteins 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 229910052737 gold Inorganic materials 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 7
- 230000016396 cytokine production Effects 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000002386 leaching Methods 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 230000019189 interleukin-1 beta production Effects 0.000 description 5
- 230000017306 interleukin-6 production Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000003672 processing method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000006433 tumor necrosis factor production Effects 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 235000005135 Micromeria juliana Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 240000002114 Satureja hortensis Species 0.000 description 2
- 235000007315 Satureja hortensis Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 2
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ONYFNWIHJBLQKE-ZETCQYMHSA-N N(6)-acetimidoyl-L-lysine Chemical compound CC(=N)NCCCC[C@H](N)C(O)=O ONYFNWIHJBLQKE-ZETCQYMHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004159 Potassium persulphate Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- VVXVTYYCCQZUKK-UHFFFAOYSA-N quercetin 3-rutinoside Natural products CC1OC(OCC2OC(OC3=C(Oc4ccc(O)c(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C(O)C2O)C(O)C(O)C1O VVXVTYYCCQZUKK-UHFFFAOYSA-N 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000031337 regulation of inflammatory response Effects 0.000 description 1
- OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 쓴메밀 추출물을 포함하는 항염증 조성물에 관한 것으로, 구체적으로 쓴메밀 추출물을 포함하며 염증성 사이토카인 발현의 억제 효과를 나타내는 항염증 조성물에 관한 것이다. The present invention relates to an anti-inflammatory composition comprising a bitter buckwheat extract, and more specifically, to an anti-inflammatory composition comprising the bitter buckwheat extract and exhibiting an inhibitory effect on the expression of inflammatory cytokines.
메밀은 마디풀과(Poygonaceae)에 속하는 일년생 식물로, 한국, 중국, 캐나다, 이탈리아 등 세계 여러 지역에서 재배되고 있는 식량 또는 경관용 작물이다. 메밀은 생육기간이 60-80일로 짧고 토양과 재배지역에 대한 적응성이 높아 작부체계상 유용한 작물로 활용되고 있다. 메밀의 대표적인 재배종으로는 일반메밀(단메밀, common buckwheat, sweet buckwheat, Fagopyrum esculentum Moench)과 쓴메밀(달단메밀, bitter buckwheat, tartary buckwheat, Fagopyrum tataricum L. Gaertn)이 있다. 일반메밀은 중국 윈난성 지역이 원산지로 작물 또는 밀원식물로 5세기 중엽 이전부터 오랫동안 재배되어 왔으며, 쓴메밀은 중국 쓰촨성, 티베트, 카슈미르와 파키스탄 북부 지역에서 야생종으로 주로 발견되며 재배역사도 비교적 짧다.Buckwheat is an annual plant belonging to the Poygonaceae family and is a food or landscape crop cultivated in many parts of the world, including Korea, China, Canada, and Italy. Buckwheat has a short growing period of 60-80 days and has high adaptability to soil and cultivation areas, so it is used as a useful crop in the cropping system. Representative cultivars of buckwheat include common buckwheat (common buckwheat, sweet buckwheat, Fagopyrum esculentum Moench) and bitter buckwheat (bitter buckwheat, tartary buckwheat, Fagopyrum tataricum L. Gaertn). Common buckwheat is native to Yunnan Province, China, and has been cultivated for a long time since before the middle of the 5th century as a crop or wheat source plant.
메밀은 쓰임새가 다양하여 종자는 메밀가루 또는 국수로 이용되며, 어린순은 메밀싹으로 주로 메밀국수, 비빔밥, 메밀묵과 함께 요리된다. 또한 껍질을 제거한 후 메밀쌀을 로스팅한 후 차로도 이용된다.Buckwheat has a variety of uses, so the seeds are used as buckwheat flour or noodles, and young sprouts are buckwheat sprouts, which are mainly cooked with buckwheat noodles, bibimbap, and buckwheat jelly. It is also used as tea after roasting buckwheat rice after removing the husk.
메밀의 종자에는 여러가지 생리활성을 나타내는 루틴(rutin), 퀘세틴(quercetin) 등의 플라보노이드 물질과 카테킨(catechins), 트리터페노이드(triterpenoids)과 같은 페놀화합류들이 존재하고 있다.Buckwheat seeds contain flavonoid substances such as rutin and quercetin, which exhibit various physiological activities, and phenolic compounds such as catechins and triterpenoids.
이러한 성분은 항산화, 항당뇨, 위 질환 효능, 항진균 및 항균활성, 고혈압 및 심혈관질환 개선, 모세혈관 건강 향상, 미백개선, 비만 예방, 항암 및 항염증 등에 효과가 있는 것으로 알려져 있다.These ingredients are known to be effective in antioxidant, antidiabetic, gastric disease efficacy, antifungal and antibacterial activity, improvement in hypertension and cardiovascular disease, improvement in capillary health, improvement in whitening, prevention of obesity, anticancer and anti-inflammation.
루틴 성분은 quercetin-3-rutinoside 또는 sophorin이라 불리며 퀘세틴(quercetin)에 루티노스(rutinose)가 결합된 물질로서 강력한 항산화능, 항염증, 항암 등에 효과가 있는 것으로 알려져 있다. 또한, 루틴은 알츠하이머를 유발시킨 마우스(mouse)에서 인지능력 향상에 도움을 주고 학습과 기억능력에도 긍정적인 영향을 주었다. 게다가 퀘세틴은 사람 구강 암세포 성장을 억제시키는데 효과적이라고 보고되었다.The rutin component is called quercetin-3-rutinoside or sophorin, and is known to have strong antioxidant, anti-inflammatory, and anti-cancer effects as a substance obtained by combining rutinose with quercetin. In addition, rutin helped improve cognitive abilities in mice with Alzheimer's and had a positive effect on learning and memory abilities. In addition, quercetin has been reported to be effective in inhibiting the growth of human oral cancer cells.
이미 잘 알려진 항산화물질로는 butylated hydroxyanisole(BHA), butylated hydroxytoluene(BHT), tert-butylhydroquinone(TBHQ) 그리고 propylgallate(PG)와 같은 합성 항산화제와 폴리페놀, 플라보노이드, 카로티노이드, 아스코르브산, 토코페롤, 인지질 등의 천연 항산화제가 있으나, 최근에는 합성 항산화제의 사용을 기피하는 추세이며 이에 따라 많은 연구자들은 안전성과 부작용에 대한 각종 질병의 예방 및 치료가 동시에 가능한 천연 항산화제 개발에 초점을 두고 연구가 이루어지고 있다. 천연 항산화제는 대부분 천연자원 유래의 항산화성 화합물로 줄기, 잎, 뿌리, 꽃, 종자 등의 많은 부분에 존재한다.Well-known antioxidants include synthetic antioxidants such as butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tert-butylhydroquinone (TBHQ), and propylgallate (PG), as well as polyphenols, flavonoids, carotenoids, ascorbic acid, tocopherols, and phospholipids. Although there are natural antioxidants, there is a trend to avoid the use of synthetic antioxidants in recent years, and many researchers are focusing on the development of natural antioxidants that can prevent and treat various diseases at the same time for safety and side effects. . Natural antioxidants are mostly antioxidant compounds derived from natural resources and are present in many parts, such as stems, leaves, roots, flowers, and seeds.
천연 항산화제는 주로 페놀화합물로서 자유라디칼(free radical) 및 활성산소의 생성억제나 활성을 저해하여 항산화 물질로서의 역할을 하는 것으로 보고되고 있다.Natural antioxidants are mainly phenolic compounds, which have been reported to act as antioxidants by inhibiting the production or activity of free radicals and active oxygen.
한편, 염증반응이란 외부로부터 물리적, 화학적 자극이나 세균감염에 대한 생체조직의 방어 반응의 하나로 손상된 조직을 재생시키는 기전이다. 염증이 만성으로 진행되면 조직을 손상하여 암으로의 진행을 유도할 수 있다. 염증반응에 관여하는 주요 세포는 대식세포(macrophage)로 알려져 있으며, 자극이나 면역세포가 분비하는 사이토카인(cytokine) 등에 의해 활성화되어, 염증성 사이토카인, NO, prostaglandin E2 (PGE2), histamine, serotonine, bradykinin, hydroxyeicosatetraenoic acid (HETE) 및 leukotriene를 생성함으로써 통증, 부종 및 열 등의 염증을 유발한다. 염증반응의 조절에는 비정상적인 자극에 다양한 면역세포가 관여하지만, 그 중 대식세포는 monocyte의 형태로 모든 조직 내에 분포하고 있어, 이상 자극에 즉각적으로 반응함으로써 염증을 유도하고 확대시키는 중요한 역할을 담당한다. 기존 연구에서 대식세포는 염증 유발물질 LPS에 의해 iNOS/NO의 생성이 증가되고 염증성 사이토카인인 TNF-α, IL-1β, IL-6 분비가 증가된다고 보고 되었으며 세포 내 신호전달 경로도 구명되었다. On the other hand, the inflammatory response is one of the defense reactions of biological tissues against physical and chemical stimuli or bacterial infections from the outside and is a mechanism for regenerating damaged tissues. When inflammation progresses chronically, it can damage tissues and induce progression to cancer. The main cells involved in the inflammatory response are known as macrophages, and are activated by stimuli or cytokines secreted by immune cells . By producing serotonine, bradykinin, hydroxyeicosatetraenoic acid (HETE) and leukotriene, it causes inflammation such as pain, swelling and fever. In the regulation of inflammatory response, various immune cells are involved in abnormal stimuli, but macrophages, among which are distributed in all tissues in the form of monocytes, play an important role in inducing and expanding inflammation by responding immediately to abnormal stimuli. In previous studies, macrophages have been reported to increase the production of iNOS/NO by the proinflammatory substance LPS and to increase the secretion of inflammatory cytokines TNF-α, IL-1β, and IL-6, and intracellular signaling pathways have also been identified.
최근 식생활의 서구화로 인한 만성퇴행성 질환 발병률과 사망률 증가에 따른 건강식에 대한 요구로 메밀에 대한 생산과 소비가 증가되고 있다. 따라서, 메밀의 다양한 용도에 대한 연구가 활발히 진행중이나(대한민국 등록특허 10-1282708), 쓴메밀 추출물을 이용한 항염증 용도에 대한 연구는 미미한 실정이다.Recently, the production and consumption of buckwheat is increasing due to the demand for healthy food due to the increase in the incidence and mortality of chronic degenerative diseases due to westernization of diet. Therefore, research on various uses of buckwheat is actively in progress (Registered Patent of the Republic of Korea 10-1282708), but studies on anti-inflammatory uses using bitter buckwheat extract are insignificant.
본 발명자들은 천연물질의 항염증 활성을 규명하기 위하여 예의 연구한 결과, 쓴메밀 추출물의 항산화 활성, NO 생성 억제 효과, 염증성 사이토카인 생성 억제 효과 및 iNOS mRNA 발현 감소효과를 통해 항염증 용도를 확인함으로써 본 발명을 완성하였다. As a result of intensive research to identify the anti-inflammatory activity of natural substances, the inventors of the present invention confirmed anti-inflammatory use through antioxidant activity, NO production inhibitory effect, inflammatory cytokine production inhibitory effect, and iNOS mRNA expression reduction effect of bitter buckwheat extract. completed the present invention.
이에, 본 발명은 쓴메밀(Tartary buckwheat) 추출물을 유효성분으로 함유하는 항염증용 조성물을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide an anti-inflammatory composition containing Tartary buckwheat extract as an active ingredient.
또한, 루틴의 함량이 증진된 쓴메밀 추출물의 제조방법을 제공하는 것을 또 다른 목적으로 한다.In addition, another object is to provide a method for producing a bitter buckwheat extract with increased rutin content.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those skilled in the art from the following description.
이에, 본 발명은 쓴메밀(Tartary buckwheat) 추출물을 유효성분으로 함유하는 항염증용 조성물을 제공한다.Accordingly, the present invention provides an anti-inflammatory composition containing Tartary buckwheat extract as an active ingredient.
본 발명의 일 구현예에서, 상기 추출물은 쓴메밀(Tartary buckwheat)을 물, C1 내지 C4의 저급 알콜, 또는 이들의 혼합용매를 사용하여 추출할 수 있다.In one embodiment of the present invention, the extract can be extracted using water, C1 to C4 lower alcohol, or a mixed solvent of bitter buckwheat (Tartary buckwheat).
본 발명의 다른 구현예에서, 상기 추출물은 에탄올을 이용하여 추출할 수 있다.In another embodiment of the present invention, the extract may be extracted using ethanol.
본 발명의 또 다른 구현예에서, 상기 쓴메밀은 염증성 사이토카인의 발현억제를 통해 항염증 활성을 나타낼 수 있다.In another embodiment of the present invention, the bitter buckwheat may exhibit anti-inflammatory activity through suppression of the expression of inflammatory cytokines.
본 발명의 또 다른 구현예에서, 상기 염증성 사이토카인은 TNF-α 또는 IL-1β일 수 있다.In another embodiment of the present invention, the inflammatory cytokine may be TNF-α or IL-1β.
본 발명의 또 다른 구현예에서, 상기 조성물은 약학 조성물일 수 있다.In another embodiment of the present invention, the composition may be a pharmaceutical composition.
본 발명의 또 다른 구현예에서, 상기 조성물은 건강기능식품 조성물일 수 있다.In another embodiment of the present invention, the composition may be a health functional food composition.
본 발명의 또 다른 구현예에서, 상기 조성물은 화장료 조성물일 수 있다.In another embodiment of the present invention, the composition may be a cosmetic composition.
또한, 본 발명은 (a) 쓴메밀을 증숙한 후 로스팅하는 단계; (b) 상기 로스팅된 쓴메밀을 분쇄하여 쓴메밀 가루를 수득하는 단계; 및 (c) 상기 가루에 용매를 통과시켜 쓴메밀 추출물을 수득하는 단계를 포함하는, 루틴의 함량이 증진된 쓴메밀 추출물의 제조방법을 제공한다.In addition, the present invention comprises the steps of (a) roasting after steaming bitter buckwheat; (b) grinding the roasted bitter buckwheat to obtain bitter buckwheat flour; And (c) providing a method for producing a bitter buckwheat extract with increased rutin content, comprising the step of passing a solvent through the powder to obtain a bitter buckwheat extract.
본 발명의 일 구현예에서, 상기 (a) 단계의 전처리 과정으로 쓴메밀을 증숙한 후 탈곡하여 껍질을 제거하고 로스팅하는 단계를 더 포함할 수 있다.In one embodiment of the present invention, after steaming bitter buckwheat in the pretreatment process of step (a), threshing to remove the skin and roasting may be further included.
본 발명의 일 구현예에서, 상기 (c)단계에서 용매를 통과시키는 것은 상기 가루를 여과필터에 넣고 92~96℃의 용매에 통과시켜 5~15분 동안 추출하는 것일 수 있다.In one embodiment of the present invention, passing the solvent in step (c) may be to extract the powder for 5 to 15 minutes by putting the powder in a filter and passing through a solvent at 92 to 96 ° C.
본 발명의 다른 구현예에서, 상기 (c)단계에서 용매를 통과시키는 것은 상기 가루를 추출기에 넣고 상온의 용매를 2~8시간 동안 통과시켜 추출하는 것일 수 있다.In another embodiment of the present invention, passing the solvent in step (c) may be to extract the powder by putting the powder in an extractor and passing the solvent at room temperature for 2 to 8 hours.
본 발명의 쓴메밀 추출물은 일반메밀 추출물에 비해 페놀함량, 플라보노이드 함량, 루틴 함량 및 퀘세틴 함량이 높아 항산화능, 항염증 효과 및 NO 생성 억제 효과가 뛰어난 것을 확인하였는 바, 본 발명에 따른 쓴메밀 추출물은 항염증용 의약품, 건강기능식품 및 화장품으로 유용하게 활용될 수 있다.The bitter buckwheat extract of the present invention has higher phenol content, flavonoid content, rutin content and quercetin content compared to the general buckwheat extract, and it was confirmed that the bitter buckwheat extract according to the present invention has excellent antioxidant activity, anti-inflammatory effect, and NO production inhibitory effect. Extracts can be usefully used as anti-inflammatory drugs, health functional foods, and cosmetics.
도 1은 일반메밀(양절메밀)과 쓴메밀(대관 3-7) 2종의 메밀 종자를 나타낸 것이다.
도 2는 표준물질과 쓴메밀 추출물 샘플의 루틴과 퀘세틴 표준물질의 피크에 대한 머무름 시간(retention time, RT)과 비교한 크로마토그램 결과를 나타낸 것이다.
도 3은 Multi-mode microplate reader로 쓴메밀 추출물의 DPPH, ABTS, 플라보노이드 및 폴리페놀 표준물질의 항산화 활성에 대한 농도별 변화를 측정한 결과를 나타낸 것이다.
도 4는 일반메밀 추출물(Common buckwheat, CB)과 쓴메밀 추출물(Tartary buckwheat, TB)의 농도별 항산화 활성을 확인한 것으로, 도 4a는 DPPH 소거 활성을 비교한 결과를 나타낸 것이고, 도 4b는 ABTS radical 소거 활성을 비교한 결과를 나타낸 것이고, 도 4c는 플라보노이드 함량을 비교한 결과를 나타낸 것이고, 도 4d는 폴리페놀 함량을 비교한 결과를 나타낸 것이다.
도 5는 RAW 264.7 세포에 일반메밀 및 쓴메밀 에탄올 추출물을 처리하고, 세포 생존율을 확인함으로써 세포독성을 비교한 결과를 나타낸 것이다.
도 6은 RAW 264.7 세포에 일반메밀 및 쓴메밀 에탄올 추출물을 처리하고, NO 생성 억제 효과를 비교한 결과를 나타낸 것이다.
도 7은 RAW 264.7 세포에 일반메밀 및 쓴메밀 에탄올 추출물을 처리하고 염증성 사이토카인 생산량을 비교한 것으로, 도 7a는 일반메밀 에탄올 추출물의 TNF-α 생산량을 나타낸 것이고, 도 7b는 쓴메밀 에탄올 추출물의 TNF-α 생산량을 나타낸 것이고, 도 7c는 일반메밀 에탄올 추출물의 IL-1β 생산량을 나타낸 것이고, 도 7d는 쓴메밀 에탄올 추출물의 IL-1β 생산량을 나타낸 것이고, 도 7e는 일반메밀 에탄올 추출물의 IL-6 생산량을 나타낸 것이고, 도 7f는 쓴메밀 에탄올 추출물의 IL-6 생산량을 나타낸 것이다.
도 8은 LPS가 자극된 RAW 264.7 세포에 일반메밀 및 쓴메밀 에탄올 추출물을 처리하고 iNOS mRNA 발현을 비교한 것으로, 도 8a는 일반메밀 에탄올 추출물의 iNOS 발현 결과를 나타낸 것이고, 도 8b는 쓴메밀 에탄올 추출물의 iNOS 발현 결과를 나타낸 것이다.
도 9는 LPS가 자극된 RAW 264.7 세포에 일반메밀 및 쓴메밀 에탄올 추출물을 처리하고 염증성 사이토카인 생산량을 비교한 것으로, 도 9a는 일반메밀 에탄올 추출물의 TNF-α 생산량을 나타낸 것이고, 도 9b는 쓴메밀 에탄올 추출물의 TNF-α 생산량을 나타낸 것이고, 도 9c는 일반메밀 에탄올 추출물의 IL-1β 생산량을 나타낸 것이고, 도 9d는 쓴메밀 에탄올 추출물의 IL-1β 생산량을 나타낸 것이고, 도 9e는 일반메밀 에탄올 추출물의 IL-6 생산량을 나타낸 것이고, 도 9f는 쓴메밀 에탄올 추출물의 IL-6 생산량을 나타낸 것이다.
도 10은 쓴메밀 가공방법에 관한 것으로, 도 10a는 탈곡된 쓴메밀 및 껍질이 있는 쓴메밀 및 탈곡된 일반메밀(알곡)의 가공단계를 나타낸 모식도이며, 도 10b는 탈곡된 쓴메밀(알곡), 껍질이 있는 쓴메밀 및 탈곡된 일반메밀(알곡)의 알갱이 또는 가루 상태를 사진으로 나타낸 것이다.
도 11은 쓴메밀 추출방식에 관한 것으로, 도 11a는 침출식(기존 고온추출방식, 콜드블루방식) 및 여과식(더치방식, 핸드드립방식) 쓴메밀 추출방법을 나타낸 모식도이며, 도 11b는 추출 방식에 따른 과정 및 실제 쓴메밀 추출 방식을 나타낸 것이고, 도 11c는 탈곡된 쓴메밀 가루 핸드드립 및 껍질이 있는 쓴메밀 가루 핸드드립 과정을 나타낸 것이다.
도 12는 추출방식에 따른 유효성분(루틴, 퀘세틴, 플라보노이드)의 함량을 비교한 결과를 나타낸 것이다.
도 13은 추출방식에 따라 쓴메밀 추출물의 선호도를 비교한 결과를 나타낸 것이다.Figure 1 shows two kinds of buckwheat seeds: general buckwheat (boiled buckwheat) and bitter buckwheat (colon 3-7).
Figure 2 shows the chromatogram results compared to the retention time (retention time, RT) for the peaks of the rutin and quercetin standards of the standard material and the bitter buckwheat extract sample.
Figure 3 shows the results of measuring the concentration-dependent changes in antioxidant activity of DPPH, ABTS, flavonoids and polyphenol standards of bitter buckwheat extract with a multi-mode microplate reader.
Figure 4 confirms the antioxidant activity by concentration of common buckwheat extract (Common buckwheat, CB) and bitter buckwheat extract (Tartary buckwheat, TB), Figure 4a shows the result of comparing DPPH scavenging activity, Figure 4b is ABTS radical Figure 4c shows the result of comparing the scavenging activity, Figure 4c shows the result of comparing the flavonoid content, and Figure 4d shows the result of comparing the polyphenol content.
Figure 5 shows the results of comparing cytotoxicity by treating raw buckwheat and bitter buckwheat ethanol extracts to RAW 264.7 cells and confirming cell viability.
Figure 6 shows the results of comparing the NO production inhibitory effect by treating RAW 264.7 cells with normal buckwheat and bitter buckwheat ethanol extracts.
Figure 7 is a comparison of the inflammatory cytokine production after treating raw buckwheat and bitter buckwheat ethanol extracts to RAW 264.7 cells, Figure 7a shows the TNF-α production of common buckwheat ethanol extract, Figure 7b is the bitter buckwheat ethanol extract It shows the TNF-α production, Figure 7c shows the IL-1β production of common buckwheat ethanol extract, Figure 7d shows the IL-1β production of bitter buckwheat ethanol extract, Figure 7e shows the IL-1β production of common
Figure 8 is LPS-stimulated RAW 264.7 cells treated with common buckwheat and bitter buckwheat ethanol extracts and compared iNOS mRNA expression, Figure 8a shows the iNOS expression results of common buckwheat ethanol extract, Figure 8b is bitter buckwheat ethanol It shows the iNOS expression result of the extract.
Figure 9 is LPS-stimulated RAW 264.7 cells treated with normal buckwheat and bitter buckwheat ethanol extracts and comparing inflammatory cytokine production, Figure 9a shows the TNF-α production of normal buckwheat ethanol extract, Figure 9b is bitter Figure 9c shows the production of TNF-α of the buckwheat ethanol extract, Figure 9c shows the production of IL-1β of the general buckwheat ethanol extract, Figure 9d shows the production of IL-1β of the bitter buckwheat ethanol extract, Figure 9e shows the general buckwheat ethanol It shows the IL-6 production of the extract, Figure 9f shows the IL-6 production of bitter buckwheat ethanol extract.
Figure 10 relates to a bitter buckwheat processing method, Figure 10a is a schematic diagram showing the processing steps of threshed bitter buckwheat, bitter buckwheat with skin, and threshed ordinary buckwheat (grain), Figure 10b is threshed bitter buckwheat (grain) , It is a photograph showing the grain or powder state of bitter buckwheat and threshed buckwheat (grain) with hull.
11 relates to a bitter buckwheat extraction method, and FIG. 11a is a schematic diagram showing bitter buckwheat extraction methods of leaching (existing high temperature extraction method, cold blue method) and filtering method (Dutch method, hand drip method), and FIG. 11b is an extraction method. It shows the process according to the method and the actual bitter buckwheat extraction method, and FIG.
Figure 12 shows the results of comparing the contents of active ingredients (rutin, quercetin, flavonoids) according to the extraction method.
Figure 13 shows the results of comparing the preference of bitter buckwheat extract according to the extraction method.
본 발명자들은 천연물질의 항염증 활성을 규명하기 위하여 예의 연구한 결과, 쓴메밀 추출물의 항산화 활성, NO 생성 억제 효과, 염증성 사이토카인 생성 억제 효과 및 iNOS mRNA 발현 감소효과를 통해 항염증 용도를 확인함으로써 본 발명을 완성하였다. As a result of intensive research to identify the anti-inflammatory activity of natural substances, the inventors of the present invention confirmed anti-inflammatory use through antioxidant activity, NO production inhibitory effect, inflammatory cytokine production inhibitory effect, and iNOS mRNA expression reduction effect of bitter buckwheat extract. completed the present invention.
이에, 본 발명은 쓴메밀(Tartary buckwheat) 추출물을 유효성분으로 함유하는 항염증용 조성물을 제공한다.Accordingly, the present invention provides an anti-inflammatory composition containing Tartary buckwheat extract as an active ingredient.
본 발명에서 사용되는 용어 "추출물"은 물질의 추출 처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. The term "extract" used in the present invention refers to an extract obtained by extraction of a substance, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a purified product or a purified product of the extract, or a mixture thereof. It includes extracts of all formulations that can be formed using the extract itself and the extract solution.
본 발명의 추출물을 제조하는 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법, 침지 추출법, 고온 및 고압 증기 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다. 본 발명에서 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있고, 물과 메탄올, 에탄올, 부탄올 등과 같은 C1 내지 C4의 저급 알코올과 이들의 혼합용매 등을 포함한 다양한 유기용매일 수 있으나, 에탄올을 이용하여 추출하는 것이 바람직하다.The method for preparing the extract of the present invention is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, reflux extraction, immersion extraction, high-temperature and high-pressure steam extraction, and the like, which may be performed alone or in combination with two or more methods. have. The type of extraction solvent used in the present invention is not particularly limited, and any solvent known in the art may be used, and water, C1 to C4 lower alcohols such as methanol, ethanol, butanol, and mixed solvents thereof, etc. It may be a variety of organic solvents including, but it is preferable to extract using ethanol.
본 발명의 일 양태에서, 상기 쓴메밀은 염증성 사이토카인의 발현억제를 통해 항염증 활성을 나타낼 수 있다. 상기 염증성 사이토카인은 염증반응에 관여하는 모든 사이토카인에 있어 제한되는 것이 아니지만, TNF-α, IL-1β 또는 IL-6인 것이 바람직하고, TNF-α 또는 IL-1β인 것이 더욱 바람직하다. In one aspect of the present invention, the bitter buckwheat may exhibit anti-inflammatory activity through suppression of the expression of inflammatory cytokines. The inflammatory cytokine is not limited to all cytokines involved in the inflammatory response, but is preferably TNF-α, IL-1β or IL-6, and more preferably TNF-α or IL-1β.
본 발명은 실시예를 통해 쓴메밀 추출물의 항염증 용도를 규명하였다.The present invention identified the anti-inflammatory use of bitter buckwheat extract through Examples.
보다 구체적으로, 본 발명의 일 실시예에서는 일반메밀에 비해 쓴메밀 추출물에서 루틴의 함량이 약 65 내지 78 배 높게 나타나는 것을 확인하였으며, 퀘세틴의 경우 일반메밀 추출물에서는 검출되지 않았으나 쓴메밀 추출물에서만 검출되는 것을 확인하였다(실시예 2 참조). 또한, 본 발명의 다른 실시예에서는 DPPH 및 ABTS radical 소거 활성법으로 쓴메밀 종자 에탄올 추출물의 항산화 활성을 평가하였으며(실시예 3 참조), LPS를 처리한 RAW 264.7 염증을 유도하고 NO를 과다 생성하는 조건에서 쓴메밀 추출물의 NO 생성 억제 효과를 확인하였고(실시예 5 참조), 염증성 사이토카인 TNF-α, IL-1β 및 IL-6의 생성억제(실시예 6 참조) 및 mRNA 발현 조절(실시예 8 참조)을 확인함으로써 쓴메밀 추출물의 항염증 효능을 확인하였으며, 쓴메밀 추출물을 처리함으로써 iNOS 단백질 및 mRNA 발현이 감소되는 것을 확인하였다(실시예 7 참조).More specifically, in one embodiment of the present invention, it was confirmed that the content of rutin was about 65 to 78 times higher in bitter buckwheat extract than in common buckwheat, and in the case of quercetin, it was not detected in ordinary buckwheat extract, but detected only in bitter buckwheat extract It was confirmed that it is (see Example 2). In addition, in another example of the present invention, the antioxidant activity of bitter buckwheat seed ethanol extract was evaluated by DPPH and ABTS radical scavenging activity methods (see Example 3), and LPS-treated RAW 264.7 induced inflammation and excessively produced NO. The NO production inhibitory effect of the bitter buckwheat extract under the conditions was confirmed (see Example 5), and the production of inflammatory cytokines TNF-α, IL-1β and IL-6 was inhibited (see Example 6) and mRNA expression was regulated (Example 5). 8), the anti-inflammatory efficacy of the bitter buckwheat extract was confirmed, and it was confirmed that iNOS protein and mRNA expression were reduced by treating the bitter buckwheat extract (see Example 7).
상기 실시예로부터 본 발명의 쓴메밀 추출물이 ABTS radical 소거 활성, NO 생성 억제, 염증성 사이토카인 TNF-α, IL-1β 및 IL-6의 생성억제, iNOS 단백질 및 mRNA 발현 억제를 통해 항염증 효능을 갖는 것을 확인하였는바, 본 발명에 따른 쓴메밀 추출물은 염증의 예방, 치료 또는 개선 용도로 약학적 조성물 또는 건강기능식품 조성물에 유용하게 이용될 수 있다.From the above examples, the bitter buckwheat extract of the present invention has anti-inflammatory efficacy through ABTS radical scavenging activity, inhibition of NO production, inhibition of production of inflammatory cytokines TNF-α, IL-1β and IL-6, and inhibition of iNOS protein and mRNA expression. As confirmed to have, the bitter buckwheat extract according to the present invention can be usefully used in pharmaceutical compositions or health functional food compositions for the purpose of preventing, treating or improving inflammation.
본 발명에 따른 조성물이 약학 조성물의 형태인 경우, 약학적으로 유효한 양의 쓴메밀 추출물을 단독으로 포함하거나 하나 이상의 약학적으로 허용되는 담체를 포함할 수 있다. 이때, 약학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아고무, 인산칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세 결정성 셀룰로스, 폴리비닐 피로리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 또한, 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.When the composition according to the present invention is in the form of a pharmaceutical composition, it may contain a pharmaceutically effective amount of bitter buckwheat extract alone or one or more pharmaceutically acceptable carriers. At this time, the pharmaceutically acceptable carrier is one commonly used in the formulation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , polyvinyl pyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, but are not limited thereto. In addition to the above components, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like may be further included.
본 발명의 약학 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여 (예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환축의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically applied) depending on the desired method, and the dosage is the condition and weight of the patient, and the degree of disease. , Depending on the drug form, administration route and time, it can be appropriately selected by those skilled in the art.
본 발명의 약학 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환축 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명 에 다른 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type, severity, drug activity, drug It may be determined according to factors including sensitivity to, time of administration, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by those skilled in the art.
구체적으로 본 발명의 약학적 조성물의 유효량은 환축의 연령, 성별, 상태, 체중, 체내에 활성 성분의 흡수도, 불활성율 및 배설속도, 질병종류, 병용되는 약물에 따라 달라질 수 있으며, 일반적으로는 체중 1 kg 당 1 내지 500 mg을 매일 또는 격일 투여하거나, 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나 투여 경로, 성별, 체중, 연령 등에 따라서 증감 될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the patient's age, sex, condition, body weight, absorption rate, inactivation rate and excretion rate of the active ingredient in the body, type of disease, and concomitant drugs, generally 1 to 500 mg per 1 kg of body weight may be administered daily or every other day, or divided into 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, gender, weight, age, etc., the dosage is not limited to the scope of the present invention in any way.
본 발명에 따른 조성물이 건강기능식품 조성물의 형태인 경우, 특정보건용 식품, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학 및 의료효과가 높은 식품으로 제조 될 수 있으며, 상기 식품은 경우에 따라, 기능성식품, 건강식품, 건강보조식품으로 혼용될 수 있으며, 유용한 효과를 얻기 위하여 정제, 캅셀, 가루, 과립, 액상, 환 등의 다양한 형태로 제조될 수 있다.When the composition according to the present invention is in the form of a health functional food composition, it can be made into a food with high medical and medical effects processed to efficiently exhibit bioregulatory functions in addition to specific health food and nutritional supply. According to, it can be mixed with functional food, health food, and health supplement food, and can be prepared in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. to obtain useful effects.
본 발명의 건강기능식품은 식품 조성물에 통상적으로 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 디히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시 톨루엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.The health functional food of the present invention may include additional ingredients that are commonly used in food compositions to improve smell, taste, and vision. For example, it may include vitamins A, C, D, E, B 1 , B 2 , B 6 , B 12 , niacin, biotin, folate, panthotenic acid, and the like. have. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), and copper (Cu) may be included. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be included. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dihydroacetate, etc.), disinfectants (bleaching powder, high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) ), etc.), coloring agents (tar color, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite, etc.), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclemate, saccharin, sodium, etc.), Food additives such as flavoring (vanillin, lactones, etc.), leavening agent (alum, D-potassium hydrogentartrate, etc.), strengthening agent, emulsifier, thickener (thickener), coating agent, gum base agent, foam inhibitor, solvent, improver, etc. can be added. The additive may be selected according to the type of food and used in an appropriate amount.
본 발명의 건강기능식품을 식품 첨가물로 사용할 경우, 이를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.When the health functional food of the present invention is used as a food additive, it may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods.
본 발명의 건강기능식품에 있어서, 쓴메밀 추출물의 함량은 특별히 제한되지 않으며, 투여 대상의 상태, 구체적인 병증의 종류, 진행 정도 등에 따라 다양하게 변경될 수 있다. 필요한 경우, 식품의 전체 함량으로도 포함될 수 있다.In the health functional food of the present invention, the content of the bitter buckwheat extract is not particularly limited, and may be variously changed depending on the condition of the subject to be administered, the type of specific disease, and the degree of progression. If necessary, it may also be included in the total content of food.
본 발명에 따른 조성물이 화장료 조성물인 경우, 피부 외용으로 사용하거나, 경구 섭취할 수 있다. When the composition according to the present invention is a cosmetic composition, it can be used for external use on the skin or taken orally.
본 발명의 화장료 조성물은 쓴메밀 추출물을 유효성분으로 함유하며 피부학적으로 허용 가능한 부형제와 함께 기초 화장품 조성물(화장수, 크림, 에센스, 클렌징 폼 및 클렌징 워터와 같은 세안제, 팩, 보디오일), 색조 화장품 조성물(화운데이션, 립스틱, 마스카라, 메이크업 베이스), 두발 제품 조성물(샴푸, 린스, 헤어컨디셔너, 헤어젤) 및 비누 등의 형태로 제조될 수 있다.The cosmetic composition of the present invention contains bitter buckwheat extract as an active ingredient and is a basic cosmetic composition (toilet, cream, essence, face wash such as cleansing foam and cleansing water, pack, body oil), color cosmetics along with dermatologically acceptable excipients It can be prepared in the form of compositions (foundation, lipstick, mascara, makeup base), hair product compositions (shampoo, rinse, hair conditioner, hair gel) and soap.
상기 부형제로는 이에 한정되지는 않으나 예를 들어, 피부연화제, 피부 침투 증강제, 착색제, 방향제, 유화제, 농화제 및 용매를 포함할 수 있다. 또한, 향료, 색소, 살균제, 산화방지제, 방부제 및 보습제 등을 추가로 포함할 수 있으며, 물성개선을 목적으로 점증제, 무기염류, 합성 고분자 물질 등을 포함할 수 있다. 예를 들면, 본 발명의 화장료 조성물로 세안제 및 비누를 제조하는 경우에는 통상의 세안제 및 비누 베이스에 상기 쓴메밀 추출물을 첨가하여 용이하게 제조할 수 있다. 크림을 제조하는 경우에는 일반적인 수중유적형(O/W)의 크림베이스에 쓴메밀 추출물 또는 이의 염을 첨가하여 제조할 수 있다. 여기에 향료, 킬레이트제, 색소, 산화방지제, 방부제 등과 물성개선을 목적으로 한 단백질, 미네랄, 비타민 등 합성 또는 천연소재를 추가로 첨가할 수 있다.The excipient is not limited thereto, but may include, for example, a skin softener, a skin penetration enhancer, a colorant, a fragrance, an emulsifier, a thickening agent, and a solvent. In addition, it may additionally include flavoring agents, pigments, bactericides, antioxidants, preservatives, moisturizing agents, and the like, and thickeners, inorganic salts, synthetic polymer materials, and the like may be included for the purpose of improving physical properties. For example, when preparing a facial cleanser and soap with the cosmetic composition of the present invention, it can be easily prepared by adding the bitter buckwheat extract to a conventional facial cleanser and soap base. When preparing a cream, it can be prepared by adding bitter buckwheat extract or a salt thereof to a general oil-in-water (O/W) cream base. Herein, synthetic or natural materials such as flavors, chelating agents, pigments, antioxidants, preservatives, and proteins, minerals, and vitamins for the purpose of improving physical properties may be additionally added.
또한, 본 발명은 (a) 쓴메밀을 증숙한 후 로스팅하는 단계; (b) 상기 로스팅된 쓴메밀을 분쇄하여 쓴메밀 가루를 수득하는 단계; 및 (c) 상기 가루에 용매를 통과시켜 쓴메밀 추출물을 수득하는 단계를 포함하는, 루틴의 함량이 증진된 쓴메밀 추출물의 제조방법을 제공한다.In addition, the present invention comprises the steps of (a) roasting after steaming bitter buckwheat; (b) grinding the roasted bitter buckwheat to obtain bitter buckwheat flour; And (c) providing a method for producing a bitter buckwheat extract with increased rutin content, comprising the step of passing a solvent through the powder to obtain a bitter buckwheat extract.
본 발명에서 쓴메밀은 껍질을 포함하는 쓴메밀 또는 껍질을 제거하여 탈곡된 쓴메밀을 알곡을 로스팅한 다음 사용할 수 있으며, 상기 쓴메밀을 알곡형태로 사용하거나 분쇄하여 가루형태로 사용할 수 있다.In the present invention, bitter buckwheat can be used after roasting grains of bitter buckwheat containing the husk or bitter buckwheat threshed by removing the husk, and the bitter buckwheat can be used in grain form or ground to be used in powder form.
상기 쓴메밀은 용매에 직접 추출하는 침출식과 필터 등에 걸러서 추출하는 여과식으로 추출 할 수 있으며 추출방식이 이에 제한되는 것은 아니다. 침출식 방식은 기존 고온 추출과 저온 추출인 콜드블루 방식을 포함하여, 여과식 추출방식은 콜드블루, 더치 및 핸드드립 방식을 포함하며, 바람직하게는 핸드드립 방식으로 추출할 수 있다.The bitter buckwheat can be extracted by an leaching method for direct extraction in a solvent and a filtration method for extraction through a filter, but the extraction method is not limited thereto. The leaching method includes the conventional high-temperature extraction and the cold blue method, which is a low-temperature extraction, and the filtering method includes cold blue, Dutch, and hand drip methods, and preferably can be extracted by hand drip method.
본 발명에서 사용되는 용어 "콜드블루" 추출방식은 물질을 상온 또는 차가운 물에 장시간 우려내 쓴맛이 덜하고 부드러운 풍미를 느낄 수 있는 추출방식을 의미하며, 본 발명에서는 탈곡된 다음 로스팅한 쓴메밀 및 껍질이 있는 상태로 로스팅한 쓴메밀을 가루 및 알곡 형태로 실온에서 추출하는 방식을 포함한다.The term "cold blue" extraction method used in the present invention refers to an extraction method in which a substance is steeped in room temperature or cold water for a long time to feel less bitter and soft flavor. It includes a method of extracting roasted bitter buckwheat in the presence of powder and grain at room temperature.
본 발명에서 사용되는 용어 "더치" 추출방식은 상온 또는 차가운 물을 속도조절을 하며 물질에 투여해 장시간에 걸쳐 우려낸 추출방식을 의미하며, 본 발명에서는 탈곡된 다음 로스팅한 쓴메밀 및 껍질이 있는 상태로 로스팅한 쓴메밀을 가루 및 알곡 형태로 실온에서 추출하는 방식을 포함한다.The term "Dutch" extraction method used in the present invention refers to an extraction method in which room temperature or cold water is administered to a material at a controlled rate and brewed over a long period of time. It includes a method of extracting roasted bitter buckwheat in the form of powder and grains at room temperature.
본 발명에서 사용되는 용어 "핸드드립" 추출방식은 중력의 원리를 이용해 필터에 뜨거운 물을 천천히 통과시켜 추출하는 여과식 추출방식을 의미하며, 본 발명에서는 탈곡된 다음 로스팅한 쓴메밀 및 껍질이 있는 상태로 로스팅한 쓴메밀을 가루 형태로 고온(92~96℃)에서 추출하는 방식을 포함한다.The term "hand drip" extraction method used in the present invention refers to a filtration extraction method in which hot water is slowly passed through a filter using the principle of gravity, and in the present invention, bitter buckwheat threshed and then roasted It includes a method of extracting roasted bitter buckwheat in a powder form at high temperature (92 ~ 96 ℃).
이하, 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나 하기의 실시예는 본 발명을 예시적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, the following examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited to these examples.
[실시예][Example]
실시예 1. 재료 준비 및 방법Example 1. Material preparation and method
1-1. 메밀 종자 준비1-1. Buckwheat Seed Preparation
강원도 평창군 대관령면(북위 37.40°, 동경 128.45°, 800 m)에 위치한 실험포장에서 2018년 7월에 파종하여 10월에 수확하고 20±5℃ 조건에서 한달간 자연건조한 일반메밀('양절메밀')과 쓴메밀('대관 3-7호') 2종의 종자를 사용하였다. 본 발명에서 사용한 2종의 종자를 도 1에 나타내었다. 건조된 종자를 분쇄기(Grinder SFM-555 SP, Shinil Co, Seoul, Korea)에서 마쇄하고 40 mesh체로 거른 후 가루를 분석에 사용하였다. 가루 시료 50 g을 측정하여 70℃의 초저온냉동고에 보관한 후 동결건조기에서 다시 건조하였다. 동결건조한 가루시료에 100배 가량의 80% 에탄올을 첨가하고 속슬렛추출기(Soxhlet heater DH-43, Jisico Sci, Seoul, Korea)를 활용하여 80℃ 항온수조에서 2시간 환류냉각추출(reflux extraction) 하여 유용 성분을 추출하였다. 추출물은 여과지(No. 6, Whatman, Maidstone, UK) 1장을 깔고 진공펌프(Vacuum Pump, GAST)로 여과한 후 볼륨 플라스크로 옮겨 100 mL로 정용하였다. 추출시료는 40℃에서 rotary evaporator(EYELA N-1000, EYELA Co, Tokyo, Japan)로 감압농축 과정을 거친 후에 70℃ 초저온에서 급속으로 동결 건조하였다. 건조된 추출물 시료의 무게를 평량하는 방법으로 추출 수율을 계산하고 일정 농도로 희석한 후 사용하였다.Normal buckwheat ('boiled buckwheat') was sown in July 2018, harvested in October, and naturally dried for a month at 20±5℃ in an experimental field located in Daegwallyeong-myeon, Pyeongchang-gun, Gangwon-do (37.40° north latitude, 128.45° east longitude, 800 m) and bitter buckwheat ('Daegwan No. 3-7') were used. Two types of seeds used in the present invention are shown in FIG. The dried seeds were ground in a grinder (Grinder SFM-555 SP, Shinil Co, Seoul, Korea), and the powder was used for analysis after sifting through a 40 mesh sieve. A 50 g powder sample was measured, stored in a cryogenic freezer at 70 ° C, and dried again in a freeze dryer. About 100 times as much 80% ethanol was added to the freeze-dried powder sample, and reflux extraction was performed in a constant temperature water bath at 80 ° C for 2 hours using a Soxhlet heater (Soxhlet heater DH-43, Jisico Sci, Seoul, Korea). Useful components were extracted. The extract was filtered with a vacuum pump (Vacuum Pump, GAST) on a sheet of filter paper (No. 6, Whatman, Maidstone, UK), and then transferred to a volumetric flask and used at a volume of 100 mL. The extracted sample was rapidly freeze-dried at 70 °C ultra-low temperature after undergoing a vacuum concentration process with a rotary evaporator (EYELA N-1000, EYELA Co, Tokyo, Japan) at 40 °C. The extraction yield was calculated by weighing the weight of the dried extract sample and used after dilution to a certain concentration.
1-2. 시약 준비1-2. reagent preparation
표준물질은 순도 99%의 루틴(Extrasynthese, Genay, France)과 퀘세틴(Extrasynthese, Genay, France) 2종을 사용하였으며, 분석에 사용된 시약으로는 HPLC 순도의 아세토니트릴과 메탄올(Tedia Co. Cincinnati, OH, USA)과 포름산(formic acid, Sigma-Aldrich Co. St. Louis, MO, USA)을 사용하였다. 증류수는 초순수증류수제조기(Milli-Q system, Millipore, Bedford, MO, USA)에서 정제한 초순수 물을 사용하였다.As standard materials, two types of 99% pure rutin (Extrasynthese, Genay, France) and quercetin (Extrasynthese, Genay, France) were used, and HPLC-purity acetonitrile and methanol (Tedia Co. Cincinnati , OH, USA) and formic acid (Sigma-Aldrich Co. St. Louis, MO, USA) were used. As distilled water, ultrapure water purified by an ultrapure distilled water maker (Milli-Q system, Millipore, Bedford, MO, USA) was used.
1-3. 루틴 및 퀘세틴 분석1-3. Rutin and quercetin assay
추출 시료는 초고속액체크로마토그래프(Ultra Performance Liquid Chromatograph, UPLC) 분석을 위해 멤브레인 필터(PTFE 13mm 0.20 μm, PALL Life Sciences, Ann Arbor, MI, USA)로 다시 여과한 후 분석전까지 -20℃ 냉동고에 보관하였다. UPLC분석은 Kim 등(2017b)의 방법으로 플라보노이드 정량 분석을 위해 UV detector를 장착한 UPLC(Acquity UPLC I-Class, Waters Corporation, Milford, MA, USA) 기기와 분석 칼럼(Acquity UPLC CSH C18, 2.1 mm i,d, 100 mm length, 1.7 μm particle size, Waters Corporation, Milford, MA, USA)을 사용하였다. 이동상으로는 용매 A(1% formic acid in water, v/v)와 용매 B(0.1% formic acid in acetonitrile, v/v)를 사용하여 유속은 0.25 mL/min으로 일정하게 흘려주었다. 용매 이송은 gradient 방식으로, 용매 B를 7%의 농도로 처음 시작하여 2분에서 11분까지 17%로 증가시켰다. 이후 11분에서 13분까지 25%로 증가시킨 후 19분까지 그 농도를 유지시켰다. 이 후 용매 B를 19분에서 21분까지 25%에서 7%로 감소시켰으며 23분까지 2분간 7%의 농도로 안정화시켰다. 기기 내 칼럼 온도는 30℃로 설정하였고, 샘플 온도는 20℃로 각각 설정하였다. 관측에 사용된 검출 파장(detection wavelength)은 259 nm이고, 시료주입량은 1 μL로 하였다. 도 2에 사용된 표준물질 루틴과 퀘세틴의 피크와 추출물 샘플의 각 피크를 표준물질의 머무름 시간(retention time, RT)과 비교하여 크로마토그램으로 나타내었다. 표준물질의 루틴과 퀘세틴 RT는 각각 9.23와 18.51 min이었다. 루틴과 퀘세틴 함량(mg/100 g, 동결건조한 종자 기준)을 표준물질의 UPLC 피크 면적을 이용하여 계산하였다. 루틴과 퀘세틴 검량선의 선형성을 검증하기 위하여 표준물질 농도별로 UPLC로 분석하여 검량곡선을 작성하고, 회귀식과 결정계수(coefficient of determination, r)를 하였다. 회귀식의 y를 피크 면적, x를 표준물질 농도로 하고, a를 기울기(slope), b를 절편(intercept)으로 하여 y=ax+b값을 계산하였다.Extracted samples were filtered again with a membrane filter (PTFE 13mm 0.20 μm, PALL Life Sciences, Ann Arbor, MI, USA) for Ultra Performance Liquid Chromatograph (UPLC) analysis and stored in a -20°C freezer until analysis. did UPLC analysis was performed using a UPLC (Acquity UPLC I-Class, Waters Corporation, Milford, MA, USA) instrument equipped with a UV detector and an analytical column (Acquity UPLC CSH C18, 2.1 mm) for quantitative analysis of flavonoids by the method of Kim et al. (2017b). i, d, 100 mm length, 1.7 μm particle size, Waters Corporation, Milford, MA, USA) were used. As the mobile phase, solvent A (1% formic acid in water, v/v) and solvent B (0.1% formic acid in acetonitrile, v/v) were used, and the flow rate was 0.25 mL/min. Solvent delivery was carried out in a gradient manner, starting with solvent B at a concentration of 7% and increasing to 17% from 2 to 11 minutes. Afterwards, the concentration was increased to 25% from 11 to 13 minutes and maintained until 19 minutes. Then, solvent B was reduced from 25% to 7% from 19 to 21 minutes and stabilized at a concentration of 7% for 2 minutes until 23 minutes. The column temperature in the instrument was set to 30 °C, and the sample temperature was set to 20 °C, respectively. The detection wavelength used for observation was 259 nm, and the sample injection amount was 1 μL. Each peak of the standard material rutin and quercetin used in Figure 2 and each peak of the extract sample was compared with the retention time (retention time, RT) of the standard material and represented as a chromatogram. Rutin and quercetin RTs of the standards were 9.23 and 18.51 min, respectively. Rutin and quercetin contents (mg / 100 g, based on lyophilized seeds) were calculated using the UPLC peak areas of standard materials. In order to verify the linearity of the rutin and quercetin calibration curves, each standard substance concentration was analyzed by UPLC, a calibration curve was prepared, and a regression equation and a coefficient of determination (r) were performed. The value of y = ax + b was calculated by taking y of the regression equation as the peak area, x as the standard concentration, a as the slope, and b as the intercept.
1-4. 항산화 활성 분석1-4. Antioxidant activity assay
시료의 항산화 활성 측정을 위해 루틴 분석과 동일한 방법으로 추출 및 여과하여 20℃ 냉동고에 보관하면서 분석용 시료로 사용하였다. 항산화 분석은 UV/VIS absorbance를 장착한 Multimode microplate reader(Cytation 5 cell imaging multimode reader, Biotek instruments Inc. Winooski, VT, USA) 기기로 측정하였다. Multi-mode microplate reader로 분석한 결과를 도 3에 나타내었다. DPPH (1,1-Diphenyl-2-picrylhydrazyl, Sigma-Aldrich) radical 소거법은 항산화 물질의 전자공여능으로 인해 환원되어 보라색이 탈색에 의해 나타내는 정도를 지표로 하여 항산화능을 측정하는 원리를 이용하였다. DPPH radical 소거 활성은 96 well plate에 표준물질과 샘플 추출물 50 μL를 첨가한 후 0.2 mM DPPH 용액(99.9% ethanol에 용해) 200 μL를 첨가한 후 실온에서 30분간 반응 후 520 nm 흡광도를 측정하였다. DPPH radical 소거 활성은 시료 100 g당 mg TE (Trolox equivalent antioxidant capacity)로 표현하였다. DPPH 보정선의 선형성을 검증하기 위하여 표준물질 농도별(0.00, 0.023, 0.034, 0.045, 0.056, 0.083 mg/mL)로 6반복으로 multi-mode microplate reader로 분석하여 검량곡선을 작성하고, 회귀식과 결정계수(coefficient of determination, r=0.9974)를 하였다. 회귀식의 y를 피크 면적, x를 표준물질 농도로 하고, a를 기울기(slope), b를 절편(intercept)으로 하여 y=ax+b값(y= 15.511x+1.4871)을 계산하였다.In order to measure the antioxidant activity of the sample, it was extracted and filtered in the same way as the routine assay, and stored in a freezer at 20 ° C., and used as a sample for analysis. Antioxidant analysis was measured using a multimode microplate reader (Cytation 5 cell imaging multimode reader, Biotek instruments Inc. Winooski, VT, USA) equipped with UV/VIS absorbance. The results of analysis with a multi-mode microplate reader are shown in FIG. 3 . The DPPH (1,1-Diphenyl-2-picrylhydrazyl, Sigma-Aldrich) radical scavenging method used the principle of measuring antioxidant activity by using the degree of purple decolorization as an indicator due to reduction due to the electron donating ability of antioxidants. DPPH radical scavenging activity was measured by adding 50 μL of standard substances and sample extracts to a 96-well plate, then adding 200 μL of 0.2 mM DPPH solution (dissolved in 99.9% ethanol), reacting at room temperature for 30 minutes, and then measuring 520 nm absorbance. DPPH radical scavenging activity was expressed as mg TE (Trolox equivalent antioxidant capacity) per 100 g of sample. In order to verify the linearity of the DPPH calibration curve, a calibration curve was prepared by analyzing with a multi-mode microplate reader in 6 repetitions at each standard concentration (0.00, 0.023, 0.034, 0.045, 0.056, 0.083 mg/mL), and the regression equation and coefficient of determination (coefficient of determination, r=0.9974) was performed. The y = ax + b value (y = 15.511x + 1.4871) was calculated by taking y of the regression equation as the peak area, x as the standard concentration, a as the slope, and b as the intercept.
ABTS(2,2'-Azino-bis-3-ethylbenzo-thiazoline-6-sulfonic acid, Sigma-Aldrich) radical 소거 활성은 추출물의 항산화 성분에 의해 ABTS+가 소거되어 radical 특유의 색인 청록색이 탈색되는 원리를 이용하였다. ABTS 7.4 mM과 potassium persulphate 2.6 mM을 하루 동안 암소에 방치하여 ABTS 양이온을 형성시킨 후 이 용액을 735 nm에서 흡광도 값이 1.4-1.5가 되도록 몰 흡광계수(ε=3.6Х104 M1·cm1)를 이용하여 메탄올로 희석하였다. ABTS radical 소거 활성은 96 well plate에 표준물질과 샘플 추출물 50 μL를 넣고, 희석된 ABTS 용액 200 μL를 첨가한 후 실온에서 60분간 반응 후 734 nm 흡광도를 측정하였다. ABTS radical 소거 활성은 시료 100 g당 mg TE로 표현하였다. ABTS 보정선의 선형성을 검증하기 위하여 표준물질 농도별(0.00, 0.023, 0.034, 0.045, 0.056, 0.083 mg/mL)로 6반복으로 multi-mode microplate reader로 분석하여 검량곡선을 작성하고, 회귀식과 결정계수(coefficient of determination, r=0.9997)를 하였다. 회귀식의 y를 피크 면적, x를 표준물질 농도로 하고, a를 기울기(slope), b를 절편(intercept)으로 하여 y=ax+b값(y= 13.918x+1.3175)을 계산하였다.ABTS (2,2'-Azino-bis-3-ethylbenzo-thiazoline-6-sulfonic acid, Sigma-Aldrich) radical scavenging activity is based on the principle that ABTS+ is scavenged by the antioxidant component of the extract and the blue-green color unique to the radical is decolored. used ABTS 7.4 mM and potassium persulphate 2.6 mM were left in the dark for one day to form ABTS cations, and then the absorbance value of this solution at 735 nm was 1.4-1.5 using the molar extinction coefficient (ε=3.6Х10 4 M1 cm1). and diluted with methanol. ABTS radical scavenging activity was measured by adding 50 μL of standard substances and sample extracts to a 96 well plate, adding 200 μL of diluted ABTS solution, reacting at room temperature for 60 minutes, and then measuring 734 nm absorbance. ABTS radical scavenging activity was expressed as mg TE per 100 g of sample. In order to verify the linearity of the ABTS calibration curve, a calibration curve was prepared by analyzing with a multi-mode microplate reader in 6 repetitions at each standard concentration (0.00, 0.023, 0.034, 0.045, 0.056, 0.083 mg/mL), and the regression equation and coefficient of determination (coefficient of determination, r=0.9997) was performed. The y = ax + b value (y = 13.918x + 1.3175) was calculated by taking y of the regression equation as the peak area, x as the standard material concentration, a as the slope, and b as the intercept.
총 플라보노이드 함량은 주황색으로 발색하는 것을 원리로 분석하였다. 96 well plate에 표준물질과 샘플 추출물 50 μL에 증류수 100 μL와 5% NaNO2 15 μL를 넣은 다음, 5분 후 10% AlCl3(H2O)6 30 μL를 가하여 6분 반응시키면 표준물질이 노란색으로 변하게 된다. 이 때 1 N NaOH 100 μL를 첨가하고, 11 분 후 표준물질이 주황색으로 변한 반응액의 흡광도 값을 510 nm에서 측정하였다. 표준물질인 rutin(Sigma-Aldrich)을 사용하여 검량선을 작성하였고, 시료 100 g당 mg rutin equivalent (RE, dry basis)로 나타내었다. 플라보노이드 보정선의 선형성을 검증하기 위하여 표준물질 농도별(0.00, 0.025, 0.050, 0.100, 0.200, 0.400 mg/mL)로 6반복으로 multi-mode microplate reader로 분석하여 검량곡선을 작성하고, 회귀식과 결정계수 (coefficient of determination, r=0.9997)를 하였다. 회귀식의 y를 피크 면적, x를 표준물질 농도로 하고, a를 기울기(slope), b를 절편 (intercept)으로 하여 y=ax+b값(y=1.7424x+0.038)을 계산하였다.The total flavonoid content was analyzed according to the principle of orange color development. In a 96 well plate, add 100 μL of distilled water and 15 μL of 5% NaNO2 to 50 μL of standard material and sample extract, then add 30 μL of 10% AlCl3(H2O)6 after 5 minutes and react for 6 minutes. The standard material turns yellow. . At this time, 100 μL of 1 N NaOH was added, and after 11 minutes, the absorbance value of the reaction solution in which the standard material turned orange was measured at 510 nm. A calibration curve was prepared using rutin (Sigma-Aldrich), a standard material, and expressed as mg rutin equivalent (RE, dry basis) per 100 g of sample. In order to verify the linearity of the flavonoid calibration curve, a calibration curve was prepared by analyzing with a multi-mode microplate reader in 6 repetitions at each standard concentration (0.00, 0.025, 0.050, 0.100, 0.200, 0.400 mg/mL), and the regression equation and coefficient of determination (coefficient of determination, r=0.9997) was performed. The y = ax + b value (y = 1.7424x + 0.038) was calculated by taking y of the regression equation as the peak area, x as the standard material concentration, a as the slope, and b as the intercept.
총 폴리페놀 함량은 Folin-Ciocalteu phenol reagent가 추출물의 폴리페놀성 화합물에 의해 환원된 결과, 몰리브덴 청색으로 발색하는 것을 원리로 분석하였다. 총 폴리페놀 함량은 96 well plate에 표준물질과 샘플 추출물 50 μL와 2% Na2CO3 용액 200 μL를 가한 후 실온에서 3분간 반응시킨 후 50% Folin-Ciocalteu reagent (Sigma-Aldrich) 20μL를 가하였다. 30분 후, 반응액의 흡광도 값을 750 nm에서 측정하였고, 표준물질인 갈릭산(Sigma-Aldrich)을 사용하여 검량선을 작성하였고, 시료 100 g당 mg gallic acid equivalent(GAE, dry basis)로 나타내었다. 폴리페놀 보정선의 선형성을 검증하기 위하여 표준물질 농도별(0.00, 0.025, 0.050, 0.100, 0.200, 0.400 mg/mL)로 6번 반복하며 multi-mode microplate reader로 분석하여 검량곡선을 작성하고, 회귀식과 결정계수(coefficient of determination, r=0.9963)를 하였다. 회귀식의 y를 피크 면적, x를 표준물질 농도로 하고, a를 기울기(slope), b를 절편(intercept)으로 하여 y=ax+b값(y=1.776x+0.0565)을 계산하였다.The total polyphenol content was analyzed based on the fact that, as a result of reduction of the Folin-Ciocalteu phenol reagent by the polyphenolic compound of the extract, the color of molybdenum blue was developed. For total polyphenol content, 50 μL of standard material and sample extract and 200 μL of 2% Na2CO3 solution were added to a 96 well plate, reacted for 3 minutes at room temperature, and 20 μL of 50% Folin-Ciocalteu reagent (Sigma-Aldrich) was added. After 30 minutes, the absorbance value of the reaction solution was measured at 750 nm, and a calibration curve was prepared using gallic acid (Sigma-Aldrich), a standard substance, and expressed as mg gallic acid equivalent (GAE, dry basis) per 100 g of sample. was In order to verify the linearity of the polyphenol calibration curve, it was repeated 6 times for each concentration of standard substance (0.00, 0.025, 0.050, 0.100, 0.200, 0.400 mg/mL) and analyzed with a multi-mode microplate reader to create a calibration curve. The coefficient of determination (r=0.9963) was performed. The y = ax + b value (y = 1.776x + 0.0565) was calculated with y as the peak area, x as the standard material concentration, a as the slope, and b as the intercept.
1-5. 세포배양1-5. cell culture
마우스의 대식세포인 RAW 264.7는 ATCC(American Type Culture Collection, Manassas, VA, USA)에서 분양을 받아 실험에 이용하였다. RAW 264.7 세포주는 배양용기에 Dulbecco's modified Eagle's minimum essential medium(DMEM, Life Technologies Inc, Brand Island, NY, USA), 10% fetal bovine serum(FBS, HycloneTM, GE healthcare life sciences, Chicago, IL, USA), 100 U/mL penicillin(HycloneTM, GE healthcare life sciences) 및 100 μg/mL streptomycine (HycloneTM, GE healthcare life sciences)을 첨가한 배양액을 이용하여 배양기에서 37℃와 5% CO2를 유지하며 배양하였다. 메밀 시료 추출물은 dimethyl sulfoxide(DMSO, Sigma-Aldrich)에 녹여 세포에 처리하였다. NO 및 염증Mouse macrophage RAW 264.7 was distributed from ATCC (American Type Culture Collection, Manassas, VA, USA) and used in the experiment. RAW 264.7 cell line was cultured in a culture vessel containing Dulbecco's modified Eagle's minimum essential medium (DMEM, Life Technologies Inc, Brand Island, NY, USA), 10% fetal bovine serum (FBS, HycloneTM, GE healthcare life sciences, Chicago, IL, USA), 100 U/mL penicillin (HycloneTM, GE healthcare life sciences) and 100 μg/mL streptomycine (HycloneTM, GE healthcare life sciences) were added to the culture medium at 37° C. and 5% CO 2 in an incubator and cultured. Buckwheat sample extract was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) and treated with cells. NO and inflammation
성 사이토카인을 확인하기 위해 LPS 1 μg/mL(Sigma Aldrich Co.)를 처리하여 RAW 264.7 대식세포에서 염증반응을 유도하였다. In order to identify sex cytokines, an inflammatory response was induced in RAW 264.7 macrophages by treatment with 1 μg/mL of LPS (Sigma Aldrich Co.).
1-6. 세포독성 측정1-6. Cytotoxicity measurement
시료의 세포독성은 MTT assay 방법으로 확인하였다. 세포를 96 well plate에 1Х105 cells/mL로 분주하여 24시간 배양하였고 시료를 6.25-400 μg/mL 농도로 처리하였다. 그 후 24시간 배양 후 MTT solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT, Sigma-Aldrich)]을 첨가하였다. 37℃, 5% CO2 배양기에서 2시간 배양한 후, 상층액을 suction하고, 형성된 formazan에 DMSO (Sigma-Aldrich)를 200 μL 첨가하고 실온에서 30분 동안 흔들면서(shaking) 녹인 다음 microplate reader를 이용하여 540 nm에서 흡광도(optical density, O.D.)를 측정하였다.The cytotoxicity of the sample was confirmed by the MTT assay method. The cells were dispensed in a 96 well plate at 1Х10 5 cells/mL and cultured for 24 hours, and the samples were treated at a concentration of 6.25-400 μg/mL. After culturing for 24 hours, MTT solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich)] was added. After culturing for 2 hours in a 37°C, 5% CO2 incubator, the supernatant was suctioned, and 200 μL of DMSO (Sigma-Aldrich) was added to the formed formazan, shaken for 30 minutes at room temperature, and then dissolved using a microplate reader. and the optical density (OD) was measured at 540 nm.
1-7. NO 생성량 측정1-7. NO production measurement
NO 생성량은 배양액 내의 nitrite 농도를 Griess reaction assay를 이용하여 측정하였다. RAW 264.7 세포는 배지를 이용하여 2Х105 cells/mL로 조절한 후 24 well plate에 분주하고, 24시간 후 시료를 농도별로 처리하였다. 1시간 후 세포에 1 μg/mL의 LPS를 처리하고 24시간 재 배양한 후, 배양액을 수거하였다. 배양액 상층액을 동량의 Griess reagent(Promega Co, Madison, WI, USA)을 첨가하여 실온에서 10분간 반응시키고 microplate reader를 이용하여 540 nm에서 흡광도를 측정하였다. 세포 배양액 내의 NO의 생성량은 표준물질인 sodium nitrite (NaNO2)의 농도별 표준곡선과 비교하여 산출하였다. NO의 positive control로는 LNIL (40 μM)을 사용하였다.The amount of NO production was measured using the Griess reaction assay for the nitrite concentration in the culture medium. RAW 264.7 cells were adjusted to 2Х10 5 cells/mL using a medium, and then dispensed into a 24-well plate, and after 24 hours, the samples were treated for each concentration. After 1 hour, the cells were treated with 1 μg/mL of LPS and re-cultured for 24 hours, and then the culture medium was collected. The same amount of Griess reagent (Promega Co, Madison, WI, USA) was added to the culture supernatant, reacted at room temperature for 10 minutes, and absorbance was measured at 540 nm using a microplate reader. The production amount of NO in the cell culture medium was calculated by comparison with the standard curve for each concentration of sodium nitrite (NaNO 2 ), a standard substance. LNIL (40 μM) was used as a positive control for NO.
1-8. 염증성 사이토카인(Cytokine) 분비량 측정1-8. Measurement of inflammatory cytokine secretion
염증성 사이토카인(Cytokine) 분비량 측정 RAW 264.7 세포에 LPS를 처리하여 염증반응을 유도한 후 생성된 염증 관련 사이토카인인 TNF-α, IL-1β 및 IL-6의 분비량을 측정하였다. RAW 264.7 세포를 24 well plate에 2Х105 cells/mL로 분주하여 24시간 배양하여 세포를 안정화시킨 뒤에 시료를 농도 별로 전처리한 뒤 1시간 후에 LPS를 1 μg/mL이 되도록 처리하였다. 24시간 배양한 후 상층액을 취하여 enzyme immunoassay(EIA) kits (BD Bio-science, Sand Diego, CA, USA)를 이용하여 kit에 제시된 실험방법대로 수행하였다.Inflammatory Cytokine Secretion Measurement RAW 264.7 cells were treated with LPS to induce an inflammatory response, and then the secretion of TNF-α, IL-1β and IL-6, which are inflammation-related cytokines, were measured. RAW 264.7 cells were dispensed in a 24 well plate at 2Х10 5 cells/mL, incubated for 24 hours to stabilize the cells, and then the samples were pretreated by concentration and treated with LPS to 1 μg/mL after 1 hour. After culturing for 24 hours, the supernatant was taken and performed according to the experimental method suggested in the kit using enzyme immunoassay (EIA) kits (BD Bio-science, Sand Diego, CA, USA).
1-9. 웨스턴블랏 분석1-9. Western blot analysis
시료를 100, 200, 400 μg/mL로 1시간 전처리 후, LPS를 1 μg/mL이 되도록 처리하여 24시간 배양한 RAW 264.7 세포를 1Хphosphate buffered saline (PBS) 용액으로 씻어 낸 뒤, lysisbuffer [50 mM HEPES (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% deoxycholate, 5 mM phenyl-metylsulfonylfluride (PMSF), 1 μg/mL aprotinin, 1% Triton X-100, and 0.1% NP-40]인 PROPREP protein extraction solution(Intron Biotechnology, Sungnam, Korea)에 용해하였다. 세포 용해액을 4℃에서 30분 반응 후, 15,000 rpm에서 30분 원심 분리하여 세포막 성분을 제거하고, 상등액만 회수하였다. 단백질의 정량은 Bradford protein assays(Bio-Rad, Hercules, CA, USA)를 사용하여 595 nm의 흡광도로 측정하였고, 이에 대한 standard로는 bovine serum albumin (BSA)를 사용하였다. 단백질 정량 후 sample buffer에 넣고 5분간 끓인 뒤 SDS-polyacrylamide gel electrophoresis(SDS-PAGE)을 이용하여 전개하였다. 전개된 gel을 PVDF membrane에 transfer한 후, 비특이적인 단백질에 대해 5% 탈지분유(non-fat milk block solution)에서 1시간 동안 실온에서 반응시킨 후, membrane에 각각의 1차 항체를 첨가하여 4℃에서 over night시켰다. 이후 Tween 20/TBS로 10분간 3번씩 세척하고, 2차 항체로는 anti-rabbit 또는 antimouse IgG-horseradish peroxidase(HRP)를 사용하여 반응시켰다. 이어서 단백질은 enhanced chemiluminescence(ECL) solution(American Pharmacia Biotech, NY, USA)을 감광시켜 Chemi-DocTM Imaging Systems(Bio-Rad)을 이용하여 발현을 확인하였다.After pre-treatment of the sample with 100, 200, or 400 μg/mL for 1 hour, RAW 264.7 cells treated with LPS to 1 μg/mL and incubated for 24 hours were washed with 1Хphosphate buffered saline (PBS) solution, and then washed with lysisbuffer [50 mM HEPES (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% deoxycholate, 5 mM phenyl-metylsulfonylfluride (PMSF), 1 μg/mL aprotinin, 1% Triton X-100, and 0.1% NP-40] PROPREP protein It was dissolved in an extraction solution (Intron Biotechnology, Sungnam, Korea). The cell lysate was reacted at 4° C. for 30 minutes and then centrifuged at 15,000 rpm for 30 minutes to remove cell membrane components and only the supernatant was recovered. Protein quantification was measured by absorbance at 595 nm using Bradford protein assays (Bio-Rad, Hercules, CA, USA), and bovine serum albumin (BSA) was used as a standard for this. After protein quantification, it was put in sample buffer, boiled for 5 minutes, and developed using SDS-polyacrylamide gel electrophoresis (SDS-PAGE). After transferring the developed gel to a PVDF membrane, reacting for non-specific proteins in 5% non-fat milk block solution for 1 hour at room temperature, adding each primary antibody to the membrane and then incubating at 4 ° C. made it over night. Thereafter, the cells were washed three times for 10 minutes with
1-10. Quantiative real-time RT-PCR에 의한 mRNA 분석1-10. mRNA analysis by quantitative real-time RT-PCR
배양된 RAW 264.7 세포에 1 mL EasyBlue reagent (Invitrogen Co., Carlsbad, CA, USA)로 세포를 분리한 후, 200 μL chloroform을 첨가하여 15,000 rpm에서 10분간 원심 분리하였다. 상층액 500 μL를 분취 한 후 동량의 isopropanol을 첨가한 뒤, 15,000 rpm으로 5분 동안 4℃에서 원심 분리하였다. 상층액을 제거하고, 1 mL DEPC-EtOH을 첨가하여 세척한 뒤 원심분리를 실시하여 상층액을 완전히 제거하였다. DEPC-DW를 첨가하여 RNA를 녹이고 Nanodrop을 이용하여 RNA 농도를 측정하였다. TOPscript TM cDNA synthesis kit (Enzynomics, Daejeon, Korea)를 이용하여 mRNA로부터 cDNA를 합성하였다. 타깃 mRNA 발현을 평가하기 위해, real-time PCR은 SYBR Premix Ex Taq (Takara Bio Inc. Shiga, Japan)을 이용하여 한 후 SYBR Thermal Cycler Dice Real-Time PCR System (Takara Bio Inc.)에서 수행하였다. 각 mRNA의 primer는 하기 [표 1]에 나타내었다.After separating the cells from the cultured RAW 264.7 cells with 1 mL EasyBlue reagent (Invitrogen Co., Carlsbad, CA, USA), 200 μL chloroform was added and centrifuged at 15,000 rpm for 10 minutes. After aliquoting 500 μL of the supernatant, the same amount of isopropanol was added, and then centrifuged at 4° C. for 5 minutes at 15,000 rpm. The supernatant was removed, washed with 1 mL DEPC-EtOH, and then centrifuged to completely remove the supernatant. RNA was dissolved by adding DEPC-DW, and RNA concentration was measured using Nanodrop. cDNA was synthesized from mRNA using the TOPscript TM cDNA synthesis kit (Enzynomics, Daejeon, Korea). To evaluate target mRNA expression, real-time PCR was performed using SYBR Premix Ex Taq (Takara Bio Inc. Shiga, Japan) followed by SYBR Thermal Cycler Dice Real-Time PCR System (Takara Bio Inc.). The primers of each mRNA are shown in [Table 1] below.
1-11. 통계 분석1-11. statistical analysis
모든 실험 결과의 측정값은 반복 실시한 결과를 평균±표준편차(mean±SD)로 나타내었고, 각 평균치간 차이에 대한 유의성은Graphpad prism software t-test와 one way ANOVA 분석을 수행하였고, 평균값의 유의성은 p-value로 검정하였다.The measured values of all experimental results were shown as mean±standard deviation (mean±SD) of repeated results, and the significance of the difference between each mean value was performed by Graphpad prism software t-test and one-way ANOVA analysis, and the significance of the mean value was tested by p -value.
실시예 2. 루틴 및 퀘세틴 함량 확인Example 2. Confirmation of rutin and quercetin content
일반메밀과 쓴메밀 종자 에탄올 추출물의 루틴과 퀘세틴 함량을 하기 [표 2]에 나타내었다. 쓴메밀의 루틴 함량은 85.1-1,386.1 mg/ 100 g로 일반메밀의 루틴 함량보다 65-78배 높았다. 퀘세틴 성분은 쓴메밀에서만 검출(19.6-286.4 mg/100 g) 되었다. The rutin and quercetin contents of common buckwheat and bitter buckwheat seed ethanol extracts are shown in [Table 2]. The rutin content of bitter buckwheat was 85.1-1,386.1 mg/100 g, which was 65-78 times higher than that of common buckwheat. Quercetin component was detected only in bitter buckwheat (19.6-286.4 mg/100 g).
(μg/mL)Cont.
(μg/mL)
(mg/100g)Rutin
(mg/100g)
(mg /100g DW)Quercetin
(mg/100g DW)
TB 2) CB1 )
200
400
100
200
400100
200
400
100
200
400
4.6±0.4
17.8±0.33)
85.1±0.8
329.7±2.53)
1,386.1±13.71.3±0.1 3)
4.6±0.4
17.8±0.3 3)
85.1±0.8
329.7±2.5 3)
1,386.1±13.7
N.D.
N.D.
19.6±4.4
68.1±3.1)
286.4±14.9ND
ND
ND
19.6±4.4
68.1±3.1 )
286.4±14.9
1)CB; common buckwheat. 1) CB; common buckwheat.
2)TB; Tartary buckwheat. 2) TB; Tartary buckwheat.
3)Mean±S.D. (n=6). 3) Mean±SD (n=6).
실시예 3. 항산화 활성 확인Example 3. Confirmation of antioxidant activity
일반메밀과 쓴메밀 종자 에탄올 추출물의 항산화 활성을 비교하기 위하여 항산화 활성은 DPPH 및 ABTS radical 소거 활성법으로 평가한 결과, 도 4a에 나타낸 바와 같이 DPPH radical 소거 활성(400 μg/mL)은 일반메밀 추출물이 223-1,138 mg TE/100 g, 쓴메밀 추출물은 292-2,317 mg TE/100 g을 나타내었다. 또한, 도 4b에 나타낸 바와 같이 일반메밀 추출물의 ABTS radical 소거 활성(400 μg/mL)은 910 mg TE/100 g과 쓴메밀 추출물은 1,076 mg TE/100 g인 것으로 나타났다. 상기 결과로부터 쓴메밀 추출물이 일반메밀 추출물보다 DPPH radical 소거능은 2.0배, ABTS radical 소거능은 1.2배 높게 나타나는 것을 확인하였다. In order to compare the antioxidant activity of common buckwheat and bitter buckwheat seed ethanol extract, the antioxidant activity was evaluated by DPPH and ABTS radical scavenging activity methods. This 223-1,138 mg TE/100 g, bitter buckwheat extract showed 292-2,317 mg TE/100 g. In addition, as shown in Figure 4b, the ABTS radical scavenging activity (400 μg / mL) of the general buckwheat extract was 910 mg TE / 100 g and the bitter buckwheat extract was 1,076 mg TE / 100 g. From the above results, it was confirmed that the DPPH radical scavenging ability of the bitter buckwheat extract was 2.0 times higher and the ABTS radical scavenging ability was 1.2 times higher than that of the general buckwheat extract.
또한, 도 4c 및 4d에 나타낸 바와 같이, 쓴메밀 추출물은 일반메밀 추출물에 비해 플라보노이드 및 폴리페놀 함량에서도 각각 최대 2.0배(1,655 mg/100 g)와 1.8배(1,370 mg/100 g) 많은 것으로 분석되었다. In addition, as shown in Figures 4c and 4d, the bitter buckwheat extract was analyzed to be up to 2.0 times (1,655 mg / 100 g) and 1.8 times (1,370 mg / 100 g), respectively, in flavonoid and polyphenol contents compared to the general buckwheat extract. It became.
실시예 4. 세포독성 평가Example 4. Cytotoxicity evaluation
항염증 평가에 사용된 RAW 264.7 세포를 대상으로 메밀 추출물의 세포독성을 MTT assay로 측정하였다. 일반메밀과 쓴메밀 추출물을 대상으로 6.25-400 μg/mL의 다양한 농도범위에서 세포독성을 평가한 결과, 도 5에 나타낸 바와 같이 세포의 생존율은 모든 처리 농도에서 100% 이상인 것으로 조사되어 세포독성이 없는 것으로 확인되었다.Cytotoxicity of buckwheat extract was measured by MTT assay on RAW 264.7 cells used for anti-inflammatory evaluation. As a result of evaluating the cytotoxicity in various concentration ranges of 6.25-400 μg / mL for general buckwheat and bitter buckwheat extracts, as shown in FIG. It was confirmed that there is no
실시예 5. NO 생성 억제 확인Example 5. Confirmation of inhibition of NO production
일반메밀과 쓴메밀 추출물의 항염증 효과를 확인하기 위해 먼저 LPS를 처리하여 RAW 264.7 세포에 염증을 유도하고 NO를 과다 생성하는 조건을 만들었다. 여기에 메밀 추출물을 처리하여 NO 생성 억제 효과를 평가하였다. 그 결과, 도 6에 나타낸 바와 같이, LPS (1 μg/mL) 단독 처리군은 처리하지 않은 군에 비해 생성된 NO의 양에서 약 10배 이상의 증가를 보여 염증반응이 충분히 활성화된 것을 확인하였다. In order to confirm the anti-inflammatory effect of common buckwheat and bitter buckwheat extracts, LPS was first treated to induce inflammation in RAW 264.7 cells and create conditions that excessively produced NO. Here, the buckwheat extract was treated to evaluate the NO production inhibitory effect. As a result, as shown in FIG. 6, it was confirmed that the LPS (1 μg/mL) alone treatment group showed an increase of about 10 times or more in the amount of NO produced compared to the untreated group, indicating that the inflammatory response was sufficiently activated.
이에 더하여, 일반메밀과 쓴메밀 추출물의 각 시료를 100, 200 및 400 μg /mL 농도로 처리한 뒤, NO 생성 억제 효과를 평가하였다. 일반메밀 추출물의 경우 모든 농도에서 유의적인 NO 생성 억제 효과가 나타나지 않았으나, 쓴메밀 추출물에서는 NO 생성량이 LPS 처리군와 비교하였을 때 농도의존적으로 억제됨을 확인하였다. 쓴메밀 추출물 100 μg/mL 처리에서는 통계적 유의성이 없었으나, 200 μg/mL과 400 μg/mL 농도에서는 통계적 유의성을 보였으며, 400 μg/mL 농도에서 LPS군 대비 10.86±4.31% 감소하였다. 쓴메밀 추출물에 의한 NO 생성 감소는 루틴(100 μM) 처리군 (7.27±2.18%)과 비슷한 결과를 나타내는 것을 확인하였다. In addition to this, each sample of common buckwheat and bitter buckwheat extract was treated at concentrations of 100, 200 and 400 μg / mL, and the NO production inhibitory effect was evaluated. In the case of the general buckwheat extract, no significant NO production inhibitory effect was shown at all concentrations, but in the bitter buckwheat extract, it was confirmed that the NO production was concentration-dependently suppressed when compared to the LPS-treated group. There was no statistical significance in the treatment with
실시예 6. 염증성 사이토카인(Pro-inflammatory cytokine) 생성 억제 효과 확인Example 6. Inhibition of inflammatory cytokine production
메밀 추출물의 염증성 사이토카인 생성에 미치는 영향을 구명하기 위해 LPS를 처리한 RAW 264.7 세포에 메밀 추출물을 농도별로 처리하여 TNF-α, IL-1β 및 IL-6의 생성량을 ELISA 방법으로 측정하였다.In order to investigate the effect of buckwheat extract on inflammatory cytokine production, LPS-treated RAW 264.7 cells were treated with buckwheat extract at each concentration, and the production of TNF-α, IL-1β and IL-6 was measured by ELISA method.
그 결과, 도 7에 나타낸 바와 같이 TNF-α와 IL-1β 생성은 일반메밀과 쓴메밀 추출물 처리에서 농도 의존적으로 유의하게 감소하는 것을 확인하였다. 특히, 일반메밀 추출물(TNF-α IC50: >400 μg/mL; IL-1β IC50: 271.24 μg/ mL)에 비해 쓴메밀 추출물(TNF-α IC50: 118.31 μg/mL: IL-1β IC50: <100 μg/mL)의 억제 효과가 현저했다. IL-6 생성은 쓴메밀 추출물(IC50: 239.07 μg/mL)처리에 의해 유의적으로 감소되는 것을 확인하였으나, 일반메밀 추출물에서는 생성 억제 효과가 거의 나타나지 않는 것을 확인하였다. As a result, as shown in Figure 7, it was confirmed that TNF-α and IL-1β production were significantly reduced in a concentration-dependent manner in the general buckwheat and bitter buckwheat extract treatment. In particular, bitter buckwheat extract (TNF-α IC50: 118.31 μg/mL: IL-1β IC50: <100 μg/mL) compared to common buckwheat extract (TNF-α IC50: >400 μg/mL; IL-1β IC50: 271.24 μg/mL). μg/mL) had a significant inhibitory effect. It was confirmed that IL-6 production was significantly reduced by treatment with the bitter buckwheat extract (IC50: 239.07 μg/mL), but it was confirmed that the normal buckwheat extract had little production inhibitory effect.
상기 결과로부터 쓴메밀 추출물은 TNF-α, IL-1β 및 IL-6의 생성을 억제하는 효과가 있는바, 초기 염증 뿐만 아니라 후천성 면역과 관련된 염증의 억제에도 효과가 있을 것임을 시사한다. From the above results, the bitter buckwheat extract has the effect of inhibiting the production of TNF-α, IL-1β and IL-6, suggesting that it will be effective in suppressing inflammation related to acquired immunity as well as early inflammation.
실시예 7. iNOS 단백질과 mRNA 발현 확인Example 7. Confirmation of iNOS protein and mRNA expression
일반 메밀 및 쓴메밀 추출물을 이용하여 iNOS 단백질 발현 정도를 확인하였다. 그 결과, 도 8에 나타낸 바와 같이 쓴메밀 추출물에서는 LPS에 의한 iNOS 단백질 발현이 감소하였으나, 일반 메밀 추출물은 LPS 처리군과 비교하여 단백질 발현에서 변화가 없거나 오히려 증가하는 것을 확인하였다. The level of iNOS protein expression was confirmed using the normal buckwheat and bitter buckwheat extracts. As a result, as shown in FIG. 8, the iNOS protein expression by LPS decreased in the bitter buckwheat extract, but it was confirmed that the normal buckwheat extract had no change or rather increased protein expression compared to the LPS-treated group.
이에 더하여, 쓴메밀 추출물에 의한 iNOS 단백질 감소가 유전자 전사 억제를 통해 나타나는 것인지 확인하기 위해 iNOS mRNA발현에 대한 영향을 측정한 결과, 도 8에 나타낸 바와 같이 쓴메밀 추출물은 농도가 높아짐에 따라 iNOS mRNA를 유의적으로 감소시켰으나, 일반 메밀 추출물은 농도 의존적인 iNOS mRNA 발현 저해를 나타내지 않았다. In addition, as a result of measuring the effect on iNOS mRNA expression in order to determine whether the reduction of iNOS protein by bitter buckwheat extract occurs through gene transcription suppression, as shown in FIG. 8, the bitter buckwheat extract increases the concentration of iNOS mRNA However, buckwheat extract did not show a concentration-dependent inhibition of iNOS mRNA expression.
따라서 쓴메밀 추출물은 iNOS mRNA발현 억제를 통해 iNOS 단백질에 의한 NO 생성을 억제하는 것으로 판단된다. 이러한 결과는 앞선 실험에서 쓴메밀 추출물이 일반메밀 추출물에 비해 NO 저해 효과가 우수한 결과와 일치하는 것을 시사한다.Therefore, it is believed that bitter buckwheat extract suppresses NO production by iNOS protein through suppression of iNOS mRNA expression. These results suggest that the bitter buckwheat extract in the previous experiment is consistent with the superior NO inhibitory effect compared to the general buckwheat extract.
실시예 8. 염증성 사이토카인(TNF-α, IL-1β 및 IL-6) mRNA 발현에 대한 영향 확인 Example 8. Confirmation of the effect on inflammatory cytokine (TNF-α, IL-1 β and IL-6) mRNA expression
메밀 추출물에 의한 염증성 사이토카인 즉, TNF-α, IL-1β 및 IL-6 생성 억제가 유전자의 발현 단계에서 조절되는지를 확인하기 위해 TNF-α, IL-1β 및 IL-6의 mRNA 발현을 조사하였다. 그 결과, 도 9에 나타낸 바와 같이 일반메밀 추출물의 경우 TNF-α와 IL-1β의 mRNA 발현은 감소되었으나, IL-6의 mRNA는 유의적인 감소를 보이지 않았다. 반면, 쓴메밀 추출물에서는 TNF-α, IL-1β 및 IL-6의 mRNA 발현이 모두 농도의존적으로 저해되는 것을 확인하였다. In order to confirm whether the suppression of inflammatory cytokines, that is, TNF-α, IL-1β, and IL-6 production by buckwheat extract is regulated at the gene expression stage, the mRNA expression of TNF-α, IL-1β, and IL-6 was investigated. did As a result, as shown in FIG. 9, in the case of the general buckwheat extract, the mRNA expression of TNF-α and IL-1β was reduced, but the mRNA of IL-6 did not show a significant decrease. On the other hand, it was confirmed that all mRNA expressions of TNF-α, IL-1β, and IL-6 were inhibited in a concentration-dependent manner in bitter buckwheat extract.
따라서 일반메밀과 쓴메밀 추출물의 염증성 사이토카인 생성량 억제효과는 관련 유전자의 발현을 저해함으로써 나타나는 것으로 판단된다. 또한 쓴메밀 추출물이 일반메밀 추출물에 비해 TNF-α, IL-1β 및 IL-6의 mRNA를 현저히 감소시킴으로써 더 우수한 항염증 효과를 나타낸다는 것을 확인하였다.Therefore, it is judged that the inhibitory effect of inflammatory cytokine production of buckwheat and bitter buckwheat extracts appears by inhibiting the expression of related genes. In addition, it was confirmed that the bitter buckwheat extract showed a superior anti-inflammatory effect by significantly reducing the mRNA of TNF-α, IL-1β and IL-6 compared to the general buckwheat extract.
실시예 9. 추출조건(온도 및 방법)에 따른 쓴메밀의 루틴 함량 확인Example 9. Confirmation of rutin content of bitter buckwheat according to extraction conditions (temperature and method)
쓴메밀을 용매를 이용하여 추출하기 위해 전처리 과정을 수행하였다. 도 10a에 나타낸 바와 같이, 전처리는 크게 원료이용 단계, 스팀 단계, 메밀쌀 단계, 로스팅 단계를 포함하는 가공방법으로 수행하였다. 원료이용 단계는 메밀 수확 후 선발작업하여 이물질을 제거하는 과정이고, 스팀단계는 선발된 종자를 고압에서 증숙하고 건조시키는 과정으로 스팀처리한 종자는 루틴 함량이 현저하게 감소되는 경향을 나타내었다. 메밀쌀 단계는 선별기에 종자를 투입하여 분류과정을 거쳐 쭉정이를 제거하고 멧돌방식으로 껍질을 분리하여 메밀쌀을 얻는 과정이며, 로스팅 단계는 로스팅 기계에 원적외선으로 70-80 ℃에서 2-3분 동안 로스팅하면 알곡이 갈색에서 노란색으로 변하게 하는 단계이다. A pretreatment process was performed to extract bitter buckwheat using a solvent. As shown in FIG. 10A, the pretreatment was largely performed by a processing method including a raw material use step, a steam step, a buckwheat rice step, and a roasting step. The raw material use step is a process of removing foreign substances by selection after harvesting buckwheat, and the steaming step is a process of steaming and drying the selected seeds at high pressure. In the buckwheat rice step, seeds are put into a sorting machine, the chaff is removed through a sorting process, and the hull is separated using a stone mill method to obtain buckwheat rice. Roasting is the stage in which the grain turns from brown to yellow.
보다 구체적으로, 도 10b 종류 1, 2에 나타낸 바와 같이, 메밀 시료의 종류를 쓴메밀을 탈곡시킨 후 볶는 탈곡 쓴메밀 및 껍질째 볶는 껍질이 있는 쓴메밀로 수행하였으며, 껍질을 제거한 탈곡 쓴메밀 및 껍질을 제거하지 않은 껍질 쓴메밀 각각의 구체적인 가공 과정을 하기에 나타내었다. More specifically, as shown in FIG. 10B Types 1 and 2, the types of buckwheat samples were threshed and then roasted threshed bitter buckwheat and bitter buckwheat with roasted skin, threshed bitter buckwheat with the skin removed and The specific processing process of each of the peeled buckwheat buckwheat is shown below.
9-1. 탈곡 쓴메밀(껍질을 제거한 쓴메밀) 가공9-1. Processing of threshed bitter buckwheat (hulled bitter buckwheat)
쓴메밀 종자를 25℃ 온도의 물에 3~4시간 동안 불리고, 스팀찜기를 사용하여 100℃에서 30~40분간 쪄서 증숙된 쓴메밀을 제조하였다. 상기 증숙된 메밀을 건조기를 이용하여 30~40℃ 온도에서 2일 내지 3일간 건조시키고, 껍질제거기를 이용하여 껍질을 제거하여 탈곡된 메밀쌀을 제조하였다. 상기 메밀쌀을 열풍식 로스터기를 사용하여 70~80℃에서 2~3분간 중배전하여 로스팅하였다. 상기 로스팅된 쓴메밀은 추출방법에 따라 알곡 또는 가루형태로 사용하였으며, 쓴메밀을 가루형태로 사용할 경우 분쇄기(R-300, FujiRoyal, Osaka, Japan)를 이용하여 분쇄하였다.Bitter buckwheat seeds were soaked in water at 25 ° C for 3 to 4 hours, and steamed at 100 ° C for 30 to 40 minutes using a steam steamer to prepare steamed bitter buckwheat. The steamed buckwheat was dried for 2 to 3 days at a temperature of 30 to 40 ° C using a dryer, and the husk was removed using a hull remover to prepare threshed buckwheat rice. The buckwheat rice was roasted by medium roasting at 70 to 80 ° C. for 2 to 3 minutes using a hot air roaster. The roasted bitter buckwheat was used in grain or powder form depending on the extraction method, and when bitter buckwheat was used in powder form, it was pulverized using a grinder (R-300, FujiRoyal, Osaka, Japan).
9-2. 껍질을 제거하지 않은 쓴메밀 가공9-2. Unhulled bitter buckwheat processing
쓴메밀 종자를 25℃ 온도의 물에 3~4시간 동안 불리고, 스팀찜기를 사용하여 100℃에서 30~40분간 쪄서 증숙된 메밀을 제조하였다. 상기 증숙된 메밀을 건조기를 이용하여 30~40℃ 온도에서 2일 내지 3일간 건조시켰다. 상기 건조된 쓴메밀을 열풍식 로스터기에서 70~80℃에서 2~3분간 중배전하여 로스팅하였다. 상기 로스팅된 쓴메밀은 추출방법에 따라 알곡 또는 가루형태로 사용하였으며, 쓴메밀을 가루형태로 사용할 경우 분쇄기(R-300, FujiRoyal, Osaka, Japan)를 이용하여 분쇄하였다.Bitter buckwheat seeds were soaked in water at a temperature of 25 ° C for 3 to 4 hours, and steamed at 100 ° C for 30 to 40 minutes using a steam steamer to prepare steamed buckwheat. The steamed buckwheat was dried for 2 to 3 days at a temperature of 30 to 40 ° C using a dryer. The dried bitter buckwheat was roasted by medium roasting at 70 to 80 ° C. for 2 to 3 minutes in a hot air roaster. The roasted bitter buckwheat was used in grain or powder form depending on the extraction method, and when bitter buckwheat was used in powder form, it was pulverized using a grinder (R-300, FujiRoyal, Osaka, Japan).
9-3. 쓴메밀 추출 방식에 따른 유효성분(루틴, 퀘세틴 및 플라보노이드) 함량 확인9-3. Confirmation of active ingredients (rutin, quercetin, and flavonoids) content according to bitter buckwheat extraction method
메밀의 추출온도 및 추출방법에 따른 루틴 함량을 확인하기 위해, 도 11에 나타낸 바와 같이, 껍질을 제거한 탈곡 쓴메밀 및 껍질을 제거하지 않은 껍질쓴메밀의 가공단계를 달리하고 침출식 또는 여과식 추출방식으로 추출한 쓴메밀 추출물의 루틴 함량을 분석하였다.In order to confirm the rutin content according to the extraction temperature and extraction method of buckwheat, as shown in FIG. 11, the processing steps of the threshed buckwheat with the skin removed and the hulled buckwheat with the skin not removed were different and leached or filtered extraction The rutin content of bitter buckwheat extract extracted by the method was analyzed.
이때, 도 11a 나타낸 바와 같이, 추출방식을 다양하게 분석하기 위해 물에 직접 담가서 추출하는 침출식과 필터 등에 걸러서 추출하는 여과식으로 분류하여 분석하였다. 여과식 추출방식으로는 도 11b에 나타낸 바와 같이, 콜드블루, 더치 및 핸드드립 방식을 이용하였다.At this time, as shown in Figure 11a, In order to analyze the extraction method in various ways, it was analyzed by categorizing it into an immersion type for extraction by immersion in water and a filtration type for extraction through filtering. As the filtration extraction method, as shown in FIG. 11b, cold blue, Dutch and hand drip methods were used.
먼저, 콜드블루 방식으로 추출물을 제조하기 위해 탈곡된 쓴메밀 및 껍질이 있는 쓴메밀의 알곡과 가루형태를 망에 담아 용기에 넣고 실온의 물을 투여한 뒤 2, 4, 6, 8시간 동안 천천히 우려낸 추출물을 이용하였다.First, in order to prepare an extract by the cold blue method, the grains and powder of bitter buckwheat and bitter buckwheat with husk are put in a net and placed in a container, water at room temperature is administered, and then slowly for 2, 4, 6, and 8 hours. The brewed extract was used.
또한, 더치 방식으로 추출물을 제조하기 위해 2, 4, 6, 8시간 동안 속도조절을 통해 실온의 물을 물방울 형태로 떨어지게 하여 탈곡된 쓴메밀 및 껍질이 있는 쓴메밀의 알곡 또는 가루에 서서히 스며들며 침출시켜 추출한 추출물을 이용하였다.In addition, in order to prepare the extract in the Dutch method, water at room temperature is allowed to fall in the form of droplets through speed control for 2, 4, 6, and 8 hours, slowly permeating and leaching into grains or powder of threshed bitter buckwheat and bitter buckwheat with skin The extract extracted by the method was used.
이에 더하여, 핸드드립 방식으로 추출물을 제조하기 위해 탈곡된 쓴메밀 및 껍질이 있는 쓴메밀의 알곡 또는 가루를 종이필터에 투여하고, 정수기 물을 이용한 저온(10~26℃) 및 고온(80~96℃)의 물을 통과시켜 추출한 추출물을 이용하였다.In addition, grains or powder of threshed bitter buckwheat and bitter buckwheat with husk are administered to a paper filter to prepare an extract by hand drip method, and low temperature (10 ~ 26 ℃) and high temperature (80 ~ 96 ℃) using water purifier ℃) was used as an extract extracted by passing water.
상기와 같이 추출방식, 온도 및 가공형태에 따라 조건을 달리하여 탈곡된 쓴메밀 또는 껍질이 있는 쓴메밀을 추출하고, 상기 추출방식에 따라 우러난 물의 루틴, 퀘세틴 및 플라보노이드의 평균 함량을 분석하여 하기 [표 3] 및 도 12에 나타내었다. as above Under different conditions depending on the extraction method, temperature and processing type, threshed bitter buckwheat or bitter buckwheat with peel was extracted, and the average contents of rutin, quercetin and flavonoids in the water brewed according to the extraction method were analyzed to obtain the following [Table 3] ] and shown in FIG. 12 .
상기 결과로부터, 종류에 있어서는 탈곡된 쓴메밀(쓴메밀 알곡), 껍질이 있는 쓴메밀, 일반메밀 추출물 순으로 루틴 추출 효율이 높은 것을 확인하였다. 또한, 처리 방법에 있어서는 침출식(콜드블루, 고온추출)에 비해 여과식(핸드드립, 더치방식)이 루틴 추출 효율 증진에 효과적임을 확인하였으며, 추출방식에 따르면 핸드드립, 더치방식, 콜드블루방식, 기존 고온 침출 방식 순으로 루틴 추출 효율이 높은 것을 확인하였다. 아울러, 처리 온도는 저온보다는 고온이 효과적이며, 시간이 길어질수록 비교적 루틴 추출이 잘 이루어 지는 것을 확인하였고, 메밀 형태별로는 알갱이에 비해 가루가 루틴 추출 효율이 더 우수하게 나타났다. From the above results, it was confirmed that rutin extraction efficiency was high in the order of threshed bitter buckwheat (bitter buckwheat grains), bitter buckwheat with hull, and general buckwheat extract in the type. In addition, it was confirmed that the filtration method (hand drip, Dutch method) is more effective in improving lutein extraction efficiency than the leaching method (cold blue, high temperature extraction) in the treatment method. According to the extraction methods, hand drip, Dutch method, and cold blue method , it was confirmed that rutin extraction efficiency was high in the order of the existing high-temperature leaching method. In addition, it was confirmed that high temperature was more effective than low temperature treatment, and that rutin extraction was performed relatively well as the time increased.
구체적으로, 탈곡 쓴메밀 추출방식에 있어서는 가루형태로 고온에서 핸드드립으로 추출하는 방식(처리 6-a)이 루틴, 퀘세틴 및 플라보노이드 함량이 가장 높은 것을 확인하였으며, 껍질 쓴메밀의 경우 가루형태의 더치 추출방식(처리 11-a) 및 핸드드립 추출방식(처리 12-a)으로 추출한 경우에 루틴 함량이 높게 나타나는 것을 확인할 수 있었다. 특히, 탈곡된 쓴메밀의 핸드드립 추출방식의 경우 대조군인 알곡 침출식 추출방식에 비해 루틴 및 플라보노이드 함량이 5배 이상, 퀘세틴 함량이 약 3배 정도 증진되는 것을 확인하였다.Specifically, in the threshing bitter buckwheat extraction method, it was confirmed that the hand drip extraction method at high temperature in powder form (Treatment 6-a) had the highest rutin, quercetin, and flavonoid contents, and in the case of peeled buckwheat, It was confirmed that the rutin content was high when extracted by the Dutch extraction method (Treatment 11-a) and the hand drip extraction method (Treatment 12-a). In particular, in the case of the hand drip extraction method of threshed bitter buckwheat, it was confirmed that the rutin and flavonoid contents were increased by 5 times or more and the quercetin content by about 3 times compared to the control grain leaching extraction method.
9-4. 쓴메밀 추출 방식에 따른 색도색차계 분석9-4. Colorimetry analysis according to bitter buckwheat extraction method
추출방식에 따라 우러나온 추출물의 우림색을 분석하기 위하여 색도색차계 결과를 확인하여 하기 [표 4]에 나타내었다. In order to analyze the rain forest color of the extract brewed according to the extraction method, the results of the color difference meter were confirmed and shown in [Table 4] below.
상기 색도색차계 결과로부터, 탈곡 쓴메밀 로스팅 또는 껍질이 있는 쓴메밀 로스팅 모두 가루 더치 방식에서 우림색이 가장 진하게 나타나는 것을 확인하였다.From the colorimetry results, it was confirmed that the darkest rain forest color appeared in the flour Dutch method in both threshed bitter buckwheat roasting and peeled bitter buckwheat roasting.
9-4. 쓴메밀 추출 방식에 따른 식미 평가9-4. Appetite evaluation according to bitter buckwheat extraction method
탈곡 쓴메밀, 껍질이 있는 쓴메밀 및 일반메밀 추출물의 추출방식에 따른 추출물의 식미를 구수한맛, 단맛, 쓴맛으로 분류하여 하기 [표 5] 및 도 13에 나타내었다. 이때, 식미 평가는 0 내지 5점으로 다음과 같이 분류하였다(0 : 느끼지 못함, 1 : 매우 약하게 느껴짐, 2 : 약하게 느껴짐, 3 : 상당히 느껴짐, 4 : 강하게 느껴짐, 5 : 매우 강하게 느껴짐).The taste of the extract according to the extraction method of threshed bitter buckwheat, bitter buckwheat with peel, and general buckwheat extract was classified into savory taste, sweet taste, and bitter taste, and is shown in [Table 5] and FIG. 13. At this time, the taste evaluation was classified as follows on a scale of 0 to 5 (0: not felt, 1: felt very weakly, 2: felt weakly, 3: felt considerably, 4: felt strongly, 5: felt very strongly).
상기 결과로부터, 탈곡 쓴메밀 또는 껍질이 있는 쓴메밀 모두 가루 더치방식, 드립, 콜드블루 6~8시간에서 가장 향이 진한 것을 확인하였다. 또한, 단맛의 경우 탈곡 쓴메밀 가루 콜드블루 방식이 가장 우수하게 나타났으며, 쓴맛의 경우 탈곡 쓴메밀 알곡로스팅 또는 껍질이 있는 쓴메밀 모두 가루 더치방식이 비교적 높은 것을 확인하였다. From the above results, it was confirmed that both threshed bitter buckwheat or bitter buckwheat with husk had the most flavor in the powder Dutch method, drip, and cold blue 6-8 hours. In addition, in the case of sweetness, the cold blue method of threshed bitter buckwheat powder showed the best, and in the case of bitterness, it was confirmed that the powder Dutch method was relatively high in roasting threshed bitter buckwheat grains or bitter buckwheat with skin.
또한, 일반 메밀에 비해 쓴메밀이 높은 선호도를 나타내는 것을 확인하였다. 특히, 쓴메밀 중에서도 쓴메밀 가루 핸드드립 저온 10분(처리 12-c)가 가장 높은 선호도를 나타냈으며, 이밖에도 탈곡된 쓴메밀 알곡 로스팅의 알갱이 콜드블루 저온 처리(처리 2-a), 쓴메밀 알곡 로스팅의 가루 콜드블루 저온 처리 8시간(처리 3-d), 쓴메밀 알곡로스팅의 알갱이 더치 저온 처리 2시간(처리 4-a), 껍찔이 있는, 껍질이 있는 쓴메밀의 알갱이 드립 저온 10분(처리 12-d)가 높은 선호도를 나타내는 것을 확인하였다. In addition, it was confirmed that bitter buckwheat showed a higher preference than general buckwheat. In particular, among the bitter buckwheat, bitter buckwheat powder hand-drip low-
상기 진술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The description of the present invention described above is for illustrative purposes, and those skilled in the art can understand that it can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. There will be. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting.
Claims (7)
(b) 상기 탈곡된 쓴메밀을 증숙한 후 로스팅하는 단계; 및
(c-1) 상기 로스팅된 쓴메밀을 용기에 넣고 92~96℃의 물을 투여하여 5~15분 동안 추출하여 쓴메밀 추출물을 수득하거나,
(c-2) 상기 로스팅된 쓴메밀을 용기에 넣고 상온의 물을 투여하여 5~15분 동안 추출하여 쓴메밀 추출물을 수득하거나,
(c-3) 상기 로스팅된 쓴메밀을 망에 담아 용기에 넣고 상온의 물을 투여하여 2~8시간 동안 추출하여 쓴메밀 추출물을 수득하거나,
(c-4) 상기 로스팅된 쓴메밀을 추출기에 넣고 상온의 물을 통과시켜 2~8시간 동안 추출하여 쓴메밀 추출물을 수득하거나,
(c-5) 상기 로스팅된 쓴메밀을 분쇄하여 쓴메밀 가루를 수득하고, 상기 가루를 여과필터에 넣고 92~96℃의 물을 통과시켜 5~15분 동안 추출하여 쓴메밀 추출물을 수득하거나,
(c-6) 상기 로스팅된 쓴메밀을 여과필터에 넣고 92~96℃의 물을 통과시켜 5~15분 동안 추출하여 쓴메밀 추출물을 수득하거나,
(c-7) 상기 로스팅된 쓴메밀을 여과필터에 넣고 상온의 물을 통과시켜 2~8시간 동안 추출하여 쓴메밀 추출물을 수득하는 단계를 포함하는, 루틴의 함량이 증진된 쓴메밀 추출물의 제조방법.(a) removing the skin by threshing Tartary buckwheat;
(b) roasting after steaming the threshed bitter buckwheat; and
(c-1) put the roasted bitter buckwheat in a container and extract it for 5 to 15 minutes by administering water at 92 to 96 ° C to obtain bitter buckwheat extract;
(c-2) put the roasted bitter buckwheat in a container and administer water at room temperature to extract for 5 to 15 minutes to obtain bitter buckwheat extract;
(c-3) Put the roasted bitter buckwheat in a net into a container, administer water at room temperature and extract for 2 to 8 hours to obtain bitter buckwheat extract,
(c-4) Put the roasted bitter buckwheat into an extractor and extract for 2 to 8 hours by passing water at room temperature to obtain bitter buckwheat extract,
(c-5) grind the roasted bitter buckwheat to obtain bitter buckwheat powder, put the powder into a filter and pass water at 92 to 96 ° C. to extract for 5 to 15 minutes to obtain bitter buckwheat extract;
(c-6) Put the roasted bitter buckwheat in a filter and extract it for 5 to 15 minutes by passing water at 92 to 96 ° C to obtain bitter buckwheat extract,
(c-7) preparing a bitter buckwheat extract with increased rutin content, comprising the step of obtaining a bitter buckwheat extract by putting the roasted bitter buckwheat in a filter and passing water at room temperature for extraction for 2 to 8 hours Way.
상기 쓴메밀(Tartary buckwheat) 추출물은 염증성 사이토카인의 발현억제를 통해 항염증 활성을 나타내는 것을 특징으로 하는, 항염증용 조성물.According to claim 2,
The bitter buckwheat (Tartary buckwheat) extract is characterized in that exhibiting anti-inflammatory activity through the inhibition of the expression of inflammatory cytokines, anti-inflammatory composition.
상기 염증성 사이토카인은 TNF-α 또는 IL-1β인 것을 특징으로 하는, 항염증용 조성물.According to claim 3,
The inflammatory cytokine is characterized in that TNF-α or IL-1β, anti-inflammatory composition.
상기 조성물은 약학 조성물인 것을 특징으로 하는, 항염증용 조성물.According to claim 2,
The composition is characterized in that the pharmaceutical composition, anti-inflammatory composition.
상기 조성물은 건강기능식품 조성물인 것을 특징으로 하는, 항염증용 조성물.According to claim 2,
The composition is characterized in that the health functional food composition, anti-inflammatory composition.
상기 조성물은 화장료 조성물인 것을 특징으로 하는, 항염증용 조성물.According to claim 2,
The composition is characterized in that the cosmetic composition, anti-inflammatory composition.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220159678A KR20220163330A (en) | 2020-06-05 | 2022-11-24 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
KR1020240017894A KR20240023560A (en) | 2020-06-05 | 2024-02-06 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200068348A KR20210151478A (en) | 2020-06-05 | 2020-06-05 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
KR1020220159678A KR20220163330A (en) | 2020-06-05 | 2022-11-24 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200068348A Division KR20210151478A (en) | 2020-06-05 | 2020-06-05 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020240017894A Division KR20240023560A (en) | 2020-06-05 | 2024-02-06 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220163330A true KR20220163330A (en) | 2022-12-09 |
Family
ID=78935173
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200068348A KR20210151478A (en) | 2020-06-05 | 2020-06-05 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
KR1020220159678A KR20220163330A (en) | 2020-06-05 | 2022-11-24 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
KR1020240017894A KR20240023560A (en) | 2020-06-05 | 2024-02-06 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200068348A KR20210151478A (en) | 2020-06-05 | 2020-06-05 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020240017894A KR20240023560A (en) | 2020-06-05 | 2024-02-06 | Composition for anti-inflammation comprising extract from Tartary buckwheat |
Country Status (1)
Country | Link |
---|---|
KR (3) | KR20210151478A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230151919A (en) | 2022-04-25 | 2023-11-02 | 주식회사 디자인셀 | Composition for antiinflammation comprising rose extract as an active ingredient |
-
2020
- 2020-06-05 KR KR1020200068348A patent/KR20210151478A/en not_active IP Right Cessation
-
2022
- 2022-11-24 KR KR1020220159678A patent/KR20220163330A/en not_active Application Discontinuation
-
2024
- 2024-02-06 KR KR1020240017894A patent/KR20240023560A/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230151919A (en) | 2022-04-25 | 2023-11-02 | 주식회사 디자인셀 | Composition for antiinflammation comprising rose extract as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
KR20210151478A (en) | 2021-12-14 |
KR20240023560A (en) | 2024-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20240023560A (en) | Composition for anti-inflammation comprising extract from Tartary buckwheat | |
KR20170094903A (en) | Composition containing complex extracts including Veratrum nigrum var. ussuriense, Juglans mandshurica, Rodgersia podophylla and Chaenomeles sinensis with antioxidant activity or whitening | |
KR20210014231A (en) | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract | |
KR20150007037A (en) | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities | |
KR102230883B1 (en) | Anticancer composition comprising herbal extract | |
KR20180044048A (en) | Composition for Preventing and Treating Neurodegenerative Diseases Comprising germinated oats extract having high-content avenanthramides | |
KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
KR20200117957A (en) | A composition for preventing or treating atopic dermatitis comprising the extract of corn silk | |
KR101403355B1 (en) | Method for producing dandelion flower Sikhae | |
KR20010077956A (en) | Method and substance for extracting antioxidant from Cynanchum wilfordii and healthful food including the powder or the antioxidant | |
KR20220046736A (en) | A composition comprising Chrysanthemum zawadskii and Cudrania tricuspidata Bureau having anti-inflammation activity | |
Lim et al. | Fagopyrum esculentum | |
KR102158661B1 (en) | Composition for preventing, ameliorating and treating inflammatory diseases comprising extract of undried immature astrigent persimmon of miyrangbansi as effective component | |
KR102486633B1 (en) | Lipid accumulation inhibitory or anti-obesity composition comprising ergosterol peroxide as an active ingredient | |
KR102671714B1 (en) | Composition for improving gastrointestinal function comprising mulberry fruit as an active ingredient | |
KR102682338B1 (en) | A Composition For Preventing, Improving Or Treating Gastrointestinal Disorders Including Extract Of Eucommia Ulmoides Oliver And Extract Of Citrus Unshiu | |
KR101651100B1 (en) | ISOLATED SINGLE COMPOUND FROM Mori Cortex Radicis ITS APPLICATION IN TREATING AND PREVENTING OBESITY | |
KR102250928B1 (en) | Cosmetic composition containing Trapa japonica Flerov callus extracts | |
KR20140083493A (en) | Composition for anti-obesity comprising extract of Sargassum fulvellum or Sargassum horneri as an effective component | |
KR102496864B1 (en) | Anti-obesity composition containing extract of Paliurus ramosissimus as an active ingredient | |
KR102167702B1 (en) | Pharmaceutical Composition Comprising Extracts of Cnidium officinale and Tribulus terrestris for Preventing or Treating Muscle Disease | |
KR102441302B1 (en) | Composition for anti-cancer containing deacetyl torilin as effective component | |
KR102682331B1 (en) | A Composition For Preventing, Improving Or Treating Gastrointestinal Disorders Including Eucommia ulmoides Oliver Extract And Red Ginseng Extract | |
KR20110078237A (en) | Composition for treating or preventing obesity containing eriobotrya japonica extract | |
KR20220157172A (en) | A Composition For Preventing, Improving Or Treating Gastrointestinal Disorders Including Extract Of Eucommia Ulmoides Oliver And Extract Of Citrus Unshiu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
E601 | Decision to refuse application | ||
E801 | Decision on dismissal of amendment |